

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 January 2011 (06.01.2011)

(10) International Publication Number
WO 2011/002409 A1

PCT

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 25/28* (2006.01)
A61K 31/4985 (2006.01)

Södertälje, SE-151 85 Södertälje (SE). **VON BERG, Stefan** [DE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE).

(21) International Application Number:
PCT/SE2010/050761

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).

(22) International Filing Date:
2 July 2010 (02.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/222,538 2 July 2009 (02.07.2009) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOLENZ, Jörg** [DE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **KARLSTRÖM, Sofia** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **KIHLSTRÖM, Jacob** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **KOLMODIN, Karin** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **LINDSTRÖM, Johan** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **RAKOS, Laszlo** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **ROTTICCI, Didier** [FR/SE]; AstraZeneca R&D Södertälje, SE-151 85 Södertälje (SE). **SWAHN, Britt-Marie** [SE/SE]; AstraZeneca R&D

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 5H-PYRROLO[3,4- ϵ]PYRAZIN-7-AMINE DERIVATIVES INHIBITORS OF BETA-SECRETASE

(57) Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A β -related pathologies such as Down's syndrome, β - amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.



WO 2011/002409 A1

5H-pyrrolo[3,4-*b*]pyrazin-7-amine derivatives inhibitors of beta-secretaseTechnical Field of the Invention

The present invention relates to novel compounds and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as medicaments for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which are inhibitors of β -secretase and hence inhibit the formation of amyloid β ($A\beta$) peptides and will be used for treatment and/or prevention of $A\beta$ -related pathologies such as Alzheimer's disease, Downs syndrome and β -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Background

The prime neuropathological event distinguishing Alzheimer's disease (AD) is deposition of the 40-42 residue amyloid β -peptide ($A\beta$) in brain parenchyma and cerebral vessels. A large body of genetic, biochemical and *in vivo* data support a pivotal role for $A\beta$ in the pathological cascade that eventually leads to AD. Patients usually present early symptoms (commonly memory loss) in their sixth or seventh decades of life. The disease progresses with increasing dementia and elevated deposition of $A\beta$. In parallel, a hyperphosphorylated form of the microtubule-associated protein tau accumulates within neurons, leading to a plethora of deleterious effects on neuronal function. The prevailing working hypothesis regarding the temporal relationship between $A\beta$ and tau pathologies states that $A\beta$ deposition precedes tau aggregation in humans and animal models of the disease. Within this context, it is worth noting that the exact molecular nature of $A\beta$, mediating this pathological function is presently an issue under intense study. Most likely, there is a continuum of toxic species ranging from lower order $A\beta$ oligomers to supramolecular assemblies such as $A\beta$ fibrils.

The A β peptide is an integral fragment of the Type I protein APP (A β amyloid precursor protein), a protein ubiquitously expressed in human tissues. Since soluble A β can be found in both plasma and cerebrospinal fluid (CSF), and in the medium from cultured cells, APP has to undergo proteolysis. There are three main cleavages of APP that are relevant to the pathobiology of AD, the so-called α -, β -, and γ -cleavages. The α -cleavage, which occurs roughly in the middle of the A β domain in APP is executed by the metalloproteases ADAM10 or ADAM17 (the latter also known as TACE). The β -cleavage, occurring at the N terminus of A β , is generated by the transmembrane aspartyl protease Beta site APP Cleaving Enzyme1 (BACE1). The γ -cleavage, generating the A β C termini and subsequent release of the peptide, is effected by a multi-subunit aspartyl protease named γ -secretase. ADAM10/17 cleavage followed by γ -secretase cleavage results in the release of the soluble p3 peptide, an N-terminally truncated A β fragment that fails to form amyloid deposits in humans. This proteolytic route is commonly referred to as the non-amyloidogenic pathway. Consecutive cleavages by BACE1 and γ -secretase generates the intact A β peptide, hence this processing scheme has been termed the amyloidogenic pathway. With this knowledge at hand, it is possible to envision two possible avenues of lowering A β production: stimulating non-amyloidogenic processing, or inhibit or modulate amyloidogenic processing. This application focuses on the latter strategy, inhibition or modulation of amyloidogenic processing.

Amyloidogenic plaques and vascular amyloid angiopathy also characterize the brains of patients with Trisomy 21 (Down's Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), and other neurodegenerative disorders.

Neurofibrillary tangles also occur in other neurodegenerative disorders including dementia-inducing disorders (Varghese, J., et al, Journal of Medicinal Chemistry, 2003, 46, 4625-4630). β -amyloid deposits are predominately an aggregate of A β peptide, which in turn is a product of the proteolysis of amyloid precursor protein (APP). More specifically, A β peptide results from the cleavage of APP at the C-terminus by one or more γ -secretases, and at the N-terminus by β -secretase enzyme (BACE), also known as aspartyl protease or Asp2 or Beta site APP Cleaving Enzyme (BACE), as part of the β -amyloidogenic pathway.

BACE activity is correlated directly to the generation of A β peptide from APP (Sinha, et al, Nature, 1999, 402, 537-540), and studies increasingly indicate that the inhibition of BACE inhibits the production of A β peptide (Roberds, S. L., et al, Human Molecular Genetics, 2001, 10, 1317-1324). BACE is a membrane bound type 1 protein that is synthesized as a partially active proenzyme, and is abundantly expressed in brain tissue. It is thought to represent the major α -secretase activity, and is considered to be the rate-limiting step in the production of amyloid- α peptide (A α).


Drugs that reduce or block BACE activity should therefore reduce A α levels and levels of fragments of A α in the brain, or elsewhere where A α or fragments thereof deposit, and thus slow the formation of amyloid plaques and the progression of AD or other maladies involving deposition of A α or fragments thereof. BACE is therefore an important candidate for the development of drugs as a treatment and/or prophylaxis of A β -related pathologies such as Down's syndrome, β -amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

It would therefore be useful to inhibit the deposition of A α and portions thereof by inhibiting BACE through inhibitors such as the compounds provided herein.

The therapeutic potential of inhibiting the deposition of A α has motivated many groups to isolate and characterize secretase enzymes and to identify their potential inhibitors, see e.g. WO2006138265, WO2009005471, WO2009005470, WO2007149033, WO2009022961.

Outline of the Invention

The present invention relates to a compound according to formula (I)



(I)

5 wherein

A is aryl or heteroaryl, wherein said aryl or heteroaryl is optionally substituted with one to three R^1 ;

G is aryl or heteroaryl, wherein said aryl or heteroaryl is optionally substituted with one to three R^2 ;

10 R^1 is selected from halogen, C_{1-4} alkyl, OR^3 , C_{3-6} carbocyclyl, C_{1-4} haloalkyl, C_{1-4} alkylOH, and hydroxy;

R^2 is selected from halogen, C_{1-3} alkoxy, C_{2-6} alkenyl, C_{1-3} alkyl, and C_{2-6} alkynyl;

R^3 is selected from C_{1-4} alkyl, C_{1-4} alkylaryl, C_{3-6} carbocyclyl, C_{1-4} alkylheteroaryl and C_{1-4} alkylOC $_{1-4}$ alkyl; and

15 R^5 is selected from fluoro and hydroxy;

m is 0, 1 or 2;

as a free base or a pharmaceutically acceptable salt thereof.

In one embodiment of the invention, A is phenyl or pyridine, substituted with one to three

20 R^1 .

In one embodiment of the invention, G is pyridine, pyrimidine or pyrazine, optionally substituted with one R^2 .

25 In one embodiment of the invention, R^1 is halogen, C_{1-4} alkyl, C_{3-6} carbocyclyl, or OR^3 . In one embodiment of the invention, R^1 is halogen, methyl, cyclopropyl or methoxy.

In one embodiment of the invention, R² is halogen or C₂₋₆alkynyl.

In one embodiment of the invention, R³ is methyl, ethyl, cyclopropyl or benzyl.

5 In one embodiment of the invention, m is 0

In another embodiment of the invention A is phenyl or pyridine;

G is pyrimidine, pyridine, or pyrazine;

R¹ is halogen, methyl, cyclopropyl, or OR³;

10 R² is halogen or C₂₋₆alkynyl;

R³ is methyl, ethyl, cyclopropyl, or CH₂Ph; and

m is zero.

15 One embodiment of the present invention is a compound selected from

5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

(*R*)- and (*S*)-5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

20 5-(3-Chloro-4-methoxy-5-methylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrazin-2-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

25 5-(3-Cyclopropyl-4-methoxyphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5-(2-Cyclopropylpyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5-(2-(Benzyloxy)pyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

30 5-(3-Fluoro-4-methoxy-5-methylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5-(4-Ethoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5-(4-Cyclopropoxy-3-fluoro-5-methylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5 7-(3-Cyclopropyl-4-methoxy-5-methyl-phenyl)-7-(3-pyrimidin-5-yl-phenyl)-7*H*-pyrrolo[3,4-*b*]pyrazin-5-ylamine;

5-(3-(5-Chloropyridin-3-yl)phenyl)-5-(2-cyclopropylpyridin-4-yl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

10 (S)-5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrazin-2-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

(R)-5-(2-Cyclopropylpyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

(S)-5-(2-Cyclopropylpyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

15 (S)-5-(4-methoxy-3,5-dimethylphenyl)-5-(3-(5-(prop-1-ynyl)pyridin-3-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

as a free base or a pharmaceutically acceptable salt thereof.

In another aspect of the invention, there is provided a pharmaceutical composition
20 comprising as active ingredient a therapeutically effective amount of a compound according formula I in association with pharmaceutically acceptable excipients, carriers or diluents.

In another aspect of the invention, there is provided that the compounds of the invention,
25 or a pharmaceutically acceptable salt thereof, can be used as medicaments, e.g. to treat or prevent A β -related pathologies.

In another aspect of the invention, there is provided that the compounds of the invention, or a pharmaceutically acceptable salt thereof, can be used for the manufacture of a
30 medicament to treat or prevent A β -related pathologies.

In another aspect of the invention, there is provided a method for the treatment of A β -related pathologies, comprising administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, to a subject, such as a mammal or a human being, in need thereof.

5

The compounds of the invention and their pharmaceutically acceptable salts thereby provides methods of treatment of A β -related pathologies, such as, but not limited to, Alzheimer's disease, Downs syndrome, β -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy and cortical basal degeneration.

10

The present invention relates to the use of compounds of formula I as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I

15

The compounds of the formula (I) may be administered in the form of a prodrug which is broken down in the human or animal body to give a compound of the formula (I). Examples of prodrugs include in vivo hydrolysable esters of a compound of the formula (I). An in vivo hydrolysable (or cleavable) ester of a compound of the formula (I) that contains a carboxy or a hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Various forms of prodrugs are known in the art.

20

The definitions set forth in this application are intended to clarify terms used throughout this application. The term "herein" means the entire application.

25

A variety of compounds in the present invention may exist in particular geometric or stereoisomeric forms. The present invention takes into account all such compounds, including cis- and trans isomers, R- and S- enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as being covered within the scope of this invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention. The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms, by synthesis from optically active starting materials, or synthesis using optically active reagents. When required, separation of the racemic material can be achieved by methods known in the art. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.

When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents, positions of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used in this application, the term "optionally substituted," means that substitution is optional and therefore it is possible for the designated atom or moiety to be unsubstituted.

As used herein, "alkyl", used alone or as a suffix or prefix, is intended to include both branched and straight chain saturated aliphatic hydrocarbon groups having from 1 to 12

carbon atoms or if a specified number of carbon atoms is provided then that specific number would be intended. For example "C₀₋₆ alkyl" denotes alkyl having 0, 1, 2, 3, 4, 5 or 6 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *sec*-butyl, *t*-butyl, pentyl, and hexyl. In the case where a subscript
5 is the integer 0 (zero) the group to which the subscript refers to indicates that the group may be absent, i.e. there is a direct bond between the groups.

As used herein, "alkenyl" used alone or as a suffix or prefix is intended to include both branched and straight-chain alkene or olefin containing aliphatic hydrocarbon groups
10 having from 2 to 12 carbon atoms or if a specified number of carbon atoms is provided then that specific number would be intended. For example "C₂₋₆alkenyl" denotes alkenyl having 2, 3, 4, 5 or 6 carbon atoms. Examples of alkenyl include, but are not limited to, vinyl, allyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-enyl, 3-methylbut-1-enyl, 1-pentenyl, 3-pentenyl and 4-hexenyl.

As used herein, "alkynyl" used also or as a suffix or prefix is intended to include to include both branched and straight-chain alkynyl or olefin containing aliphatic hydrocarbon groups having from 2 to 12 carbon atoms or if a specified number of carbon atoms is provided then that specific number would be intended. For example ethynyl, propynyl (e.g. 1-
20 propynyl, 2-propynyl), 3-butyne, pentynyl, hexynyl and 1-methylpent-2-ynyl.

As used herein, "aromatic" refers to hydrocarbonyl groups having one or more unsaturated carbon ring(s) having aromatic characters, (e.g. $4n + 2$ delocalized electrons) and comprising up to about 14 carbon atoms. In addition "heteroaromatic" refers to groups
25 having one or more unsaturated rings containing carbon and one or more heteroatoms such as nitrogen, oxygen or sulphur having aromatic character (e.g. $4n + 2$ delocalized electrons).

As used herein, the term "aryl" refers to an aromatic ring structure made up of from 5 to 14
30 carbon atoms. Ring structures containing 5, 6, 7 and 8 carbon atoms would be single-ring aromatic groups, for example, phenyl. Ring structures containing 8, 9, 10, 11, 12, 13, or 14 would be polycyclic, for example naphthyl. The aromatic ring can be substituted at one or

more ring positions with such substituents as described above. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, for example, the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.

As used herein, the term "cycloalkyl" is intended to include saturated ring groups, having the specified number of carbon atoms. These may include fused or bridged polycyclic systems. Preferred cycloalkyls have from 3 to 10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, and 6 carbons in the ring structure. For example, "C₃₋₆ cycloalkyl" denotes such groups as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

As used herein, the term "cycloalkenyl" is intended to include unsaturated ring groups, having the specified number of carbon atoms. These may include fused or bridged polycyclic systems. Preferred cycloalkenyls have from 3 to 10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, and 6 carbons in the ring structure. For example, "C₃₋₆ cycloalkenyl" denotes such groups as cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl.

As used herein, "halo" or "halogen" refers to fluoro, chloro, bromo, and iodo.

"Counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, tosylate, benzenesulfonate, and the like.

As used herein, the term "heterocyclyl" or "heterocyclic" or "heterocycle" refers to a saturated, unsaturated or partially saturated, monocyclic, bicyclic or tricyclic ring (unless otherwise stated) containing 3 to 20 atoms of which 1, 2, 3, 4 or 5 ring atoms are chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group is optionally be replaced by a -C(O)-; and where unless stated to the contrary a ring nitrogen or sulphur atom is optionally oxidised to form the N-oxide or S-oxide(s) or a ring nitrogen is optionally quarternized; wherein a ring -NH is optionally substituted by acetyl, formyl, methyl or mesyl; and a ring is optionally

substituted by one or more halo. It is understood that when the total number of S and O atoms in the heterocyclyl exceeds 1, then these heteroatoms are not adjacent to one another. If the said heterocyclyl group is bi- or tricyclic then at least one of the rings may optionally be a heteroaromatic or aromatic ring provided that at least one of the rings is non-heteroaromatic. If the said heterocyclyl group is monocyclic then it must not be aromatic. Examples of heterocyclyls include, but are not limited to, piperidinyl, *N*-acetylpiperidinyl, *N*-methylpiperidinyl, *N*-formylpiperazinyl, *N*-mesylpiperazinyl, homopiperazinyl, piperazinyl, azetidiny, oxetanyl, morpholinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolinyl, tetrahydropyranyl, dihydro-2*H*-pyranyl, tetrahydrofuranyl, tetrahydro-thiopyranyl, tetrahydro-thiopyran 1-oxide, tetrahydro-thiopyran 1,1-dioxide, 1*H*-pyridin-2-one, and 2,5-dioxoimidazolidinyl.

As used herein, "heteroaryl" refers to a heteroaromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroaryl groups include without limitation, pyridyl (i.e., pyridinyl), pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl (i.e. furanyl), quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrol, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, benzoxazolyl, aza-benzoxazolyl, imidazothiazolyl, benzo[1,4]dioxinyl, benzo[1,3]dioxolyl and the like. In some embodiments, the heteroaryl group has from 1 to 20 carbon atoms, and in further embodiments from 3 to 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to 14, 4 to 14, 3 to 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to 4, 1 to 3, or 1 to 2 heteroatoms. In some embodiments, the heteroaryl group has 1 heteroatom.

As used herein, the phrase "protecting group" means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones respectively. The field of protecting group

chemistry has been reviewed (Greene, T.W.; Wuts, P.G.M. *Protective Groups in Organic Synthesis*, 3rd ed.; Wiley: New York, 1999).

As used herein, “pharmaceutically acceptable” is employed herein to refer to those
5 compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

10 As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the
15 non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such non-toxic salts include those derived from inorganic acids such as hydrochloric acid.

The pharmaceutically acceptable salts of the present invention can be synthesized from the
20 parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like diethyl ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.

25 As used herein, “tautomer” means other structural isomers that exist in equilibrium resulting from the migration of a hydrogen atom. For example, keto-enol tautomerism where the resulting compound has the properties of both a ketone and an unsaturated alcohol.

As used herein “stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

5 Compounds of the invention further include hydrates and solvates.

The present invention further includes isotopically-labelled compounds of the invention. An “isotopically” or “radio-labelled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass
10 number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to ^2H (also written as D for deuterium), ^3H (also written as T for tritium), ^{11}C , ^{13}C , ^{14}C , ^{13}N , ^{15}N , ^{15}O , ^{17}O , ^{18}O , ^{18}F , ^{35}S , ^{36}Cl , ^{82}Br , ^{75}Br , ^{76}Br , ^{77}Br , ^{123}I , ^{124}I , ^{125}I and ^{131}I . The radionuclide that is incorporated in the instant
15 radio-labelled compounds will depend on the specific application of that radio-labeled compound. For example, for *in vitro* receptor labelling and competition assays, compounds that incorporate ^3H , ^{14}C , ^{82}Br , ^{125}I , ^{131}I , ^{35}S or will generally be most useful. For radio-imaging applications ^{11}C , ^{18}F , ^{125}I , ^{123}I , ^{124}I , ^{131}I , ^{75}Br , ^{76}Br or ^{77}Br will generally be most useful.

20

It is understood that a “radio-labelled compound” is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of ^3H , ^{14}C , ^{125}I , ^{35}S and ^{82}Br .

25 Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracically, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.

30 The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician,

when determining the individual regimen and dosage level as the most appropriate for a particular patient.

The quantity of the compound to be administered will vary for the patient being treated and will vary from about 100 ng/kg of body weight to 100 mg/kg of body weight per day. For instance, dosages can be readily ascertained by those skilled in the art from this disclosure and the knowledge in the art. Thus, the skilled artisan can readily determine the amount of compound and optional additives, vehicles, and/or carrier in compositions and to be administered in methods of the invention.

In another aspect of the invention, there is provided a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according formula I in association with pharmaceutically acceptable excipients, carriers or diluents.

In another aspect of the invention, there is provided a method of inhibiting activity of BACE with a compound according to formula I.

In another aspect of the invention, there is provided a method of treating or preventing an A β -related pathology in a mammal, such as a human being, comprising administering to said patient a therapeutically effective amount of a compound according to formula I, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor, wherein said A β -related pathology is Alzheimer Disease.

The treatment of A β -related pathology defined herein may be applied as a mono therapy or may involve, in addition to the compound of the invention, conjoint treatment with conventional therapy of value in treating one or more disease conditions referred to herein. Such conventional therapy may include one or more of the following categories of agents: acetyl cholinesterase inhibitors, anti-inflammatory agents, cognitive and/or memory enhancing agents or atypical antipsychotic agents. Cognitive enhancing agents, memory enhancing agents and acetyl choline esterase inhibitors includes, but not limited to, donepezil (Aricept), galantamine (Reminyl or Razadyne), rivastigmine (Exelon), tacrine

(Cognex) and memantine (Namenda, Axura or Ebixa). Atypical antipsychotic agents includes, but not limited to, olanzapine (marketed as Zyprexa), aripiprazole (marketed as Abilify), risperidone (marketed as Risperdal), quetiapine (marketed as Seroquel), clozapine (marketed as Clozaril), ziprasidone (marketed as Geodon) and olanzapine/fluoxetine (marketed as Symbyax).

Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of the invention.

Additional conventional therapy may include one or more of the following categories of agents:

(i) antidepressants such as agomelatine, amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, duloxetine, elzasonan, escitalopram, fluvoxamine, fluoxetine, gepirone, imipramine, ipsapirone, maprotiline, nortriptyline, nefazodone, paroxetine, phenelzine, protriptyline, ramelteon, reboxetine, robalzotan, sertraline, sibutramine, thionisoxetine, tranlycypromaine, trazodone, trimipramine, venlafaxine and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(ii) atypical antipsychotics including for example quetiapine and pharmaceutically active isomer(s) and metabolite(s) thereof.

(iii) antipsychotics including for example amisulpride, aripiprazole, asenapine, benzisoxidil, bifeprunox, carbamazepine, clozapine, chlorpromazine, debenzapine, divalproex, duloxetine, eszopiclone, haloperidol, iloperidone, lamotrigine, loxapine, mesoridazine, olanzapine, paliperidone, perlapine, perphenazine, phenothiazine, phenylbutylpiperidine, pimozide, prochlorperazine, risperidone, sertindole, sulpiride, suproclonidine, suriclone, thioridazine, trifluoperazine, trimetozine, valproate, valproic acid, zopiclone, zotepine, ziprasidone and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(iv) anxiolytics including for example alnespirone, azapirones, benzodiazepines, barbiturates such as adinazolam, alprazolam, balezepam, bentazepam, bromazepam, brotizolam, buspirone, clonazepam, clorazepate, chlordiazepoxide, cyprazepam, diazepam, diphenhydramine, estazolam, fenobam, flunitrazepam, flurazepam, fosazepam, lorazepam, lormetazepam, meprobamate, midazolam, nitrazepam, oxazepam, prazepam, quazepam, reclazepam, tracazolate, trepipam, temazepam, triazolam, uldazepam, zolazepam and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(v) anticonvulsants including for example carbamazepine, clonazepam, ethosuximide, felbamate, fosphenytoin, gabapentin, lacosamide, lamotrogine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, rufinamide, topiramate, valproate, vigabatrin, zonisamide and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(vi) Alzheimer's therapies including for example donepezil, rivastigmine, galantamine, memantine, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(vii) Parkinson's therapies including for example deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegiline and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(viii) migraine therapies including for example almotriptan, amantadine, bromocriptine, butalbital, cabergoline, dichloralphenazone, dihydroergotamine, eletriptan, frovatriptan, lisuride, naratriptan, pergolide, pizotifen, pramipexole, rizatriptan, ropinirole, sumatriptan, zolmitriptan, zomitriptan, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(ix) stroke therapies including for thrombolytic therapy with eg activase and desmoteplase, abciximab, citicoline, clopidogrel, eptifibatide, minocycline, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

5 (x) urinary incontinence therapies including for example darafenacin, falvoxate, oxybutynin, propiverine, robalzotan, solifenacin, tolterodine and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(xi) neuropathic pain therapies including for example lidocain, capsaicin, and
10 anticonvulsants such as gabapentin, pregabalin, and antidepressants such as duloxetine, venlafaxine, amitriptyline, klomipramine, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(xii) nociceptive pain therapies such as paracetamol, NSAIDS and coxibs, such as
15 celecoxib, etoricoxib, lumiracoxib, valdecoxib, parecoxib, diclofenac, loxoprofen, naproxen, ketoprofen, ibuprofen, nabumeton, meloxicam, piroxicam and opioids such as morphine, oxycodone, buprenorfin, tramadol, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

20 (xiii) insomnia therapies including for example agomelatine, allobarbitol, alonimid, amobarbitol, benzocetamine, butobarbitol, capuride, chloral, cloperidone, clorethate, dexclamol, ethchlorvynol, etomidate, glutethimide, halazepam, hydroxyzine, mecloqualone, melatonin, mephobarbitol, methaqualone, midaflur, nisobamate, pentobarbitol, phenobarbitol, propofol, ramelteon, roletamide, triclofos, secobarbitol,
25 zaleplon, zolpidem and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.

(xiv) mood stabilizers including for example carbamazepine, divalproex, gabapentin, lamotrigine, lithium, olanzapine, quetiapine, valproate, valproic acid, verapamil, and
30 equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.


Such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active compound or compounds within approved dosage ranges and/or the dosage described in the publication reference.

5 Methods of preparation

The present invention also relates to processes for preparing the compound of formula (I) as a free base or a pharmaceutically acceptable salt thereof. Throughout the following description of such processes it is to be understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are for example described in *Protective Groups in Organic Synthesis* by T.W. Greene, P.G.M Wutz, 3rd Edition, Wiley-Interscience, New York, 1999. It is to be understood that microwaves can alternatively be used for the heating of reaction mixtures.

Another aspect of the present invention provides a process for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof, which process (wherein A, G, R¹, R², R³, R⁵ and m are, unless otherwise specified, as defined in formula (I)) comprises of:


(i) *Formation of a compound of formula (VII)*



Scheme 1

A compound of formula (VII) may be obtained as depicted in Scheme 1, for example by reacting a 3-carbamoylpyrazine-2-carboxylic acid of formula (II) with methyl chloroformate (III) in the presence of an amine (IV) like triethyl amine or ethyldiisopropylamine to give a compound of formula (V). The compound of formula (V) is further reacted with an organometallic reagent $M-R^{20}$ (VI), *e.g.* an organomagnesium reagent, wherein R^{20} is an optionally substituted aryl or heteroaryl group, to form a compound of formula (VII).

(ii) *Formation of a compound of formula (X)*




Scheme 2

A compound of formula (X) may be obtained by reacting a compound of formula (VII) with a compound of formula (VIII) (Scheme 2), wherein R^{21} is alkyl (such as for example *tert*-butyl). The reaction is performed in the presence of a suitable Lewis acid of formula (IX), wherein R^{22} is alkyl (such as ethyl or isopropyl). The reaction is performed in a suitable solvent (such as diethyl ether, tetrahydrofuran or 2-methyltetrahydrofuran) at a temperature between room temperature and reflux temperature. Compound (VIII) can be either a racemate or an enantiomerically enriched or enantiopure compound. If compound (VIII) is an optically pure enantiomer the enantiomerically pure compound (X) may be obtained.

(iii) *Formation of a compound of formula (XII)*


20



Scheme 3

A compound of formula (XII) may be prepared as shown in Scheme 3 by treating a compound of formula (X), with an appropriate organo metallic reagent of formula (XI) wherein M is a metal (such as lithium, zinc or magnesium or a combination thereof), L is a ligand (such as halogen) and n is between 0 and 2, and R²³ is an optionally substituted aryl or heteroaryl group, followed by treatment with a suitable acid, such as hydrochloric acid. The reaction may be performed in a suitable solvent, such as diethyl ether or tetrahydrofuran, at a temperature between -105 °C and room temperature. The organo metallic reagent of formula (XI) may be generated from the corresponding LG-R²³, wherein LG represents a leaving group such as a halogen, such as iodide, bromide or or chloride by known methods as described in Advanced Organic Chemistry by Jerry March, 4th edition, Wiley Interscience. If an enantiomerically pure, or enriched, compound (X) is used in this reaction, an enantiomerically pure or enantiomerically enriched compound (XII) may be obtained.

(iv) Formation of a compound of formula (I)



Scheme 4

A compound of formula (I) (*Scheme 4*) may be obtained by starting from, for example, a compound of formula (XII), and reacting said compound (XII) with a boronic acid or a boronic ester or a stannane of formula $T-R^G$ (XIII), wherein T is for example $B(OH)_2$, $B(Oalkyl)_2$, or SnR_3 , and R^G is defined as for G above, under the influence of a transition metal catalyst. Such a catalyst could be a palladium catalyst, such as [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride, tetrakis(triphenylphosphine)-palladium(0), palladium diphenylphosphineferrocene dichloride, palladium(II) acetate or bis(dibenzylideneacetone) palladium (0). Optionally, a suitable ligand such as triphenylphosphine, tri-*tert*-butylphosphine or 2-(dicyclohexylphosphino)biphenyl, or zinc and sodium triphenylphosphinetrimetasulfonate, is used. A suitable base, such as cesium fluoride, an alkyl amine, such as triethyl amine, or an alkali metal or alkaline earth metal carbonate or hydroxide such as potassium carbonate, sodium carbonate, cesium carbonate, or sodium hydroxide, may be used in the reaction. Said reaction may be performed at a temperature range between +20 °C and +160 °C, in a suitable solvent, such as toluene, tetrahydrofuran, dioxane, dimethoxyethane, water, ethanol, *N,N*-dimethylacetamide or *N,N*-dimethylformamide, or mixtures thereof. If an enantiomerically pure or enriched compound (XII) is used in this reaction, an enantiomerically pure or enantiomerically enriched compound (I) may be obtained.

The compound $T-R^G$ of formula (XIII) may be generated from the corresponding $LG-R^G$, wherein LG represents a leaving group, such as a halogen, (such as iodide, bromide or chlorine) by known methods as described in for example *Advanced Organic Chemistry* by Jerry March 4th edition, Wiley Interscience.

Compounds of formula (II), (III), (IV), (V), (VI), (VIII), (IX), (XI) and (XIII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Terms and abbreviations:

atm	atmospheric pressure;
ACN	acetonitrile;
aq	aqueous;

	Boc	<i>t</i> -butoxycarbonyl;
	Cbz	benzyloxycarbonyl;
	dba	dibenzylideneacetone;
	DCM	dichloromethane;
5	DIBAL-H	diisobutylaluminium hydride;
	DIPEA	diisopropylethylamine;
	DME	dimethoxyethane;
	DMF	<i>N,N</i> -dimethyl formamide;
	DMSO	dimethyl sulfoxide;
10	Et ₂ O	diethyl ether;
	EtOAc	ethyl acetate;
	equiv	equivalent;
	h	hour(s);
	HPLC	high pressure (performance) liquid chromatography;
15	min	minute(s).;
	MeOH	methanol;
	MS	mass spectrometry;
	NMR	nuclear magnetic resonance;
	o.n.	over night
20	psi	pounds per square inch;
	rt	room temperature;
	sat	saturated;
	SFC	supercritical fluid chromatography;
	TFA	trifluoroacetic acid;
25	THF	tetrahydrofuran;
	TMEDA	tetramethylethylenediamine;
	TLC	thin layer chromatography;
	UPLC	ultra performance liquid chromatography
	X-Phos	2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl

30

General methods:

All solvents used were of analytical grade and commercially available anhydrous solvents were routinely used for reactions. Starting materials used were available from commercial sources, or prepared according to literature procedures. Room temperature refers to 20 – 25 C. Solvent mixture compositions are given as volume percentages or volume ratios.

5

Microwave heating was performed in a Biotage Creator, Initiator or Smith Synthesizer Single-mode microwave cavity producing continuous irradiation at 2450 MHz. It is understood that microwaves can be used for the heating of reaction mixtures.

10 Thin layer chromatography (TLC) was performed on Merck TLC-plates (Silica gel 60 F₂₅₄) and spots were UV visualized. Flash chromatography was performed on a Combi Flash® Companion™ using RediSep™ normal-phase flash columns. Straight phase flash column chromatography was manually performed on Merck Silica gel 60 (0.040-0.063mm), or automatically using an ISCO Combiflash® Companion™ system using the
15 solvent system indicated. Phase separation was optionally performed on an Isolute® phase separator.

¹H NMR spectra were recorded in the indicated deuterated solvent at 400 MHz unless otherwise indicated. Spectra were obtained using a Bruker av400 NMR spectrometer
20 operating at 400 MHz for ¹H and 100 MHz for ¹³C equipped with a 3 mm flow injection SEI ¹H/D-¹³C probe head with Z-gradients, using a BEST 215 liquid handler for sample injection, or using a Bruker DPX400 NMR spectrometer operating at 400 MHz for ¹H, 376 MHz for ¹⁹F, and 100 MHz for ¹³C, equipped with a 4-nucleus probehead with Z-gradients. 500 MHz spectra were recorded using a Bruker 500MHz Avance III NMR spectrometer,
25 operating at 500 MHz for ¹H, 125 MHz for ¹³C, and 50 MHz for ¹⁵N equipped with a 5mm TXI probehead with Z-gradients. 600 MHz spectra were recorded using a Bruker DRX600 NMR spectrometer, operating at 600 MHz for ¹H, 150 MHz for ¹³C, and 60 MHz for ¹⁵N equipped with a 5mm TXI (or BBO) probehead with Z-gradients. Chemical shifts are given in ppm down- and upfield from TMS (0.00 ppm). The following reference signals
30 were used: TMS 0.00, or the residual solvent signal of DMSO-d₆ 2.49, CD₃OD 3.30, acetone-d₆ 2.04 or CDCl₃ 7.25 (unless otherwise indicated). Resonance multiplicities are

denoted s, d, t, q, m, br and app for singlet, doublet, triplet, quartet, multiplet, broad and apparent, respectively. In some cases only diagnostic signals are reported.

HPLC analyses were performed on an Agilent HP1100 system consisting of a G1322A
5 Micro Vacuum Degasser, a G1311A Quaternary Pump, a G1367 Well-Plate Autosampler,
a G1316A Thermostatted Column Compartment and a G1315A Diode Array Detector. The
column used was an Xbridge C8 30x50mm, 3.5 μ m or a Gemini C18, 3.0 x 50 mm, 3.0 μ m,
110 Å run at a flow rate of 1.0 ml/min. Alternatively, HPLC analyses were performed on
an Agilent HP1100 system consisting of a G1379A Micro Vacuum Degasser, a G1312A
10 Binary Pump, a G1367 Well-Plate Autosampler, a G1316A Column Compartment and a
G1315B Diode Array Detector. The column used was an Xbridge C8 30x50mm, 3.5 μ m or
a Gemini C18, 3.0 x 50 mm, 3.0 μ m, 110 Å run at a flow rate of 1.0 ml/min. Alternatively,
HPLC analyses were performed on an Agilent HP1100 system consisting of a G1322A
Micro Vacuum Degasser, a G1312A Binary Pump, a G1367 Well-Plate Autosampler, a
15 G1316A Thermostatted Column Compartment and a G1315A Diode Array Detector. The
column used was an Xbridge C8 30x50mm, 3.5 μ m or a Gemini C18, 3.0 x 50 mm, 3.0 μ m,
110 Å run at a flow rate of 1.0 ml/min.

GC analyses were performed on a HP 6890 GC equipped with a G1512AX flame
20 ionization detector supplied by Agilent Technologies. The column used was DB-5 MS, ID
0.18 mm x 10m, 0.18 μ m (J&W Scientific). A linear temperature gradient was typically
applied. Chiral GC analyses were performed on an HP 6890 GC equipped with a flame
ionization detector supplied by Agilent Technologies. The column used was a Cyclodex B
ID 0.25 mm x 30 m, 0.25 μ m (Agilent Technologies). The temperature of the GC oven was
25 typically held isocratically at for example 100 °C for 30 minutes.

Mass spectra (MS) were run using an automated system with atmospheric pressure
chemical (APCI or CI) or electrospray (+ESI) ionization. Generally, only spectra where
parent masses are observed are reported. The lowest mass major ion is reported for
30 molecules where isotope splitting results in multiple mass spectral peaks (for example
when chlorine is present). UPLC-MS analyses were performed on a Waters Acquity UPLC
system consisting of an Acquity Autosampler, Acquity Sample Organizer, Acquity

Column Manager, Acquity Binary Solvent Manager, Acquity UPLC PDA detector and a Waters 3100 Mass Spectrometer. The mass spectrometer was equipped with an electrospray ion source (ES) operated in positive and negative ion mode. Separation was performed on an Acquity column, UPLC BEH, C18 1.7 μ M run at a flow rate of 0.5 ml/min. Alternatively, UPLCMS analyses were performed on a Waters Acquity UPLC system consisting of an Acquity Solvent Manager, Acquity Sample Organizer, Acquity Column Manager, Acquity Binary Solvent Manager, Acquity PDA detector and a Waters SQ Detector. The mass spectrometer was equipped with an electrospray ion source (ES) operated in positive and negative ion mode. Separation was performed on an Acquity column, UPLC BEH, C18 1.7 μ M run at a flow rate of 0.5 ml/min.

LC-MS analyses were performed on an LC-MS system consisting of a Waters Alliance 2795 HPLC, a Waters PDA 2996 diode array detector, a Sedex 75 ELS detector and a ZQ 2000 single quadrupole mass spectrometer. The mass spectrometer was equipped with an electrospray ion source (ES) operated in positive and negative ion mode. Separation was performed on a Xbridge C18, 30x50mm, 3.5 μ m column or on a Gemini C18 3.0 x 50, 3 mm (Phenomenex) column run at a flow rate of 1 ml/min. Alternatively, LC-MS analyses were performed on an LC-MS consisting of a Waters sample manager 2777C, a Waters 1525 binary pump, a Waters 1500 column oven, a Waters ZQ single quadrupole mass spectrometer, a Waters PDA2996 diode array detector and a Sedex 85 ELS detector. The mass spectrometer was equipped with an electrospray ion source (ES) operated in positive and negative ion mode. The column used was a Xbridge C18, 30x50mm, 3.5 μ m or a Gemini C18, 3.0 mm x 50 mm, 3 mm, (Phenomenex) which was run at a flow rate of 1 ml/min. Alternatively, LC-MS analyses were performed on a LC-MS consisting of a Waters sample manager 2777C, a Waters 1525 binary pump, a Waters 1500 column oven, a Waters ZQ single quadrupole mass spectrometer, a Waters PDA2996 diode array detector and a Sedex 85 ELS detector. The mass spectrometer was configured with an atmospheric pressure chemical ionisation (APCI) ion source which was further equipped with atmospheric pressure photo ionisation (APPI) device. The mass spectrometer operated in positive and negative ion mode, switching between APCI and APPI mode. Separation was performed using a Gemini column C18, 3.0 mm x 50 mm, 3 mm, (Phenomenex) and run at a flow rate of 0.8 ml/min. Typical mobile phase systems for HPLC, UPLC-MS, and

LCMS consisted of A: 10mM NH₄OAc (aq.) in 5% CH₃OH) or 10mM NH₄OAc in 5% CH₃CN and B: CH₃OH or CH₃CN and linear gradients from 100% A to 100% B was typically applied.

5 GCMS analysis was performed on a GC/DIP-MS system supplied by Agilent Technologies. The system consisted of a GC 6890N, G1530N, a G2614A Auto-sampler, G2613A injector and a G2589N mass spectrometer. The mass spectrometer was equipped with a Direct Inlet Probe (DIP) interface manufactured by SIM GmbH. The mass spectrometer was equipped with an electron impact (EI) ion source and the electron
10 voltage was set to 70 eV. The mass spectrometer scanned between m/z 50-550 and the scan speed was set to 2.91 scan/s. The sample solution was either injected on the GC or introduced by direct inlet to the probe tip. The GC column used was a DB-5 MS, ID 0.18 mm x 10m, 0.18 μ m (J&W Scientific) or a VF-5 MS, ID 0.25 mm x 15m, 0.25 μ m (Varian Inc.). A linear temperature gradient was typically applied. Alternatively, GCMS analysis
15 was performed on a GC-MS system supplied by Agilent Technologies, consisting of a 6890N G1530N GC, a G2614A Auto-sampler, G2613A injector and a G2589N mass spectrometer. The column used was a DB-5 MS, ID 0.18 mm x 10m, 0.18 μ m (J&W Scientific) or a VF-5 MS, ID 0.25 mm x 30m, 0.25 μ m (Varian Inc.). Typically a linear temperature gradient was applied. The mass spectrometer was equipped with a chemical
20 ionisation (CI) ion source and the reactant gas was methane or the mass spectrometer was equipped with an electron impact (EI) ion source and the electron voltage was set to 70 eV. The mass spectrometer scanned between m/z 50-500 and the scan speed was set to 3.21 scan/s.

25 Preparative HPLC was performed on a Waters Auto purification HPLC-UV system with a diode array detector using for example a Waters Xterra® MS C₈ column (30x150 mm, 10 μ m), a Phenomex Gemini-NX column (21x250 mm, 10 μ m), a Waters XBridge C8 column (19x250 mm, 10 μ m), or a Waters XBridge™ C18 column (19x250 mm, 10 μ m). Mobile phase A: 0.1 M ammonium acetate in water/mobile phase B (95:5). Mobile phase B:
30 MeCN or MeOH. Typically a linear gradient of mobile phase B was applied.

Preparative chiral chromatography for separation of enantiomers was run on a Berger Multigram II system (SFC) or a LaPrep® system (HPLC) using the specified column and mobile phase system.


- 5 Compounds have been named using CambridgeSoft MedChem ELN v2.1 or ACD/Name, version 9.0, 10.0, or 10.06, software from Advanced Chemistry Development, Inc. (ACD/Labs), Toronto ON, Canada, www.acdlabs.com, 2004, or Lexichem, version 1.7, software from OpenEye.

10 EXAMPLES

Below follows a number of non-limiting examples of compounds of the invention.

Example 1i

Methyl 3-cyanopyrazine-2-carboxylate




- Pyrazine-2,3-dicarboxylic acid monoamide (10.79 g, 64.56 mmol) was slurried in DCM (100 mL). Triethylamine (18.85 mL, 135.58 mmol) was added and the mixture was cooled to 0 °C. Methyl chloroformate (10.97 mL, 142.04 mmol) was added dropwise, and the mixture was allowed to reach rt and stirred for 2h. Water and NaHCO₃(sat) ~1:1 were
20 added and the mixture was extracted with DCM. The organic phase were washed with water twice, dried over MgSO₄ and concentrated to give 9.15g (87%).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.05 (q, 2 H) 3.98 (s, 3 H); MS (CI) *m/z* 164 [M+1]⁺.

25 Example 2i

3-(4-Methoxy-3,5-dimethylbenzoyl)pyrazine-2-carbonitrile




Magnesium turnings (1.676 g, 68.96 mmol) were stirred under Ar(g) for 10min and LiCl 0.5M in THF (100 mL, 50.11 mmol) was added followed by DIBAL-H (1M in THF) (0.230 mL, 0.23 mmol). The mixture was stirred for 5 min and 5-bromo-2-methoxy-1,3-dimethylbenzene (10.38 g, 48.27 mmol) was added in one portion and stirred for 3h. The mixture was transferred over 60 min to a cooled solution of methyl 3-cyanopyrazine-2-carboxylate (7.5 g, 45.97 mmol) in THF (60 mL) at -78 °C. The mixture was stirred at -78 °C for 20min before water was added. Most of the solvent was evaporated and NH₄Cl (sat) was added. The mixture was extracted with DCM and the organic phase was passed through a phase separator (Sorbent) and concentrated. Chromatography on silica using 0 - 50% EtOAc in *n*-heptane as eluent, gave 9.3g (76%) of the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.06 - 9.09 (m, 1 H) 9.04 - 9.06 (m, 1 H) 7.68 (s, 2 H) 3.75 (s, 3 H) 2.28 (s, 6 H); MS (CI) *m/z* 268 [M+1]⁺.


Example 3i

N-((3-Cyanopyrazin-2-yl)(4-methoxy-3,5-dimethylphenyl)methylene)-2-methylpropane-2-sulfinamide




Titanium(IV) ethoxide (17.46 g, 76.55 mmol) was dissolved in THF (150 mL) and 3-(4-methoxy-3,5-dimethylbenzoyl)pyrazine-2-carbonitrile (9.3 g, 34.79 mmol) was added followed by 2-methyl-2-propanesulfinamide (5.48 g, 45.23 mmol). The mixture was heated to 60 °C for 72 h and subsequently cooled to rt. MeOH (20mL) and EtOAc (80 mL) was added followed by NaHCO₃ (sat) (2 mL). The mixture was stirred at rt for 10min. Silica gel was added and the mixture was concentrated to dryness. Chromatography on silica using 0 - 40% EtOAc in heptane as eluent, gave 8.62g (67%) of the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.03 (br. s., 1 H) 8.94 (d, 1 H) 7.31 (s, 2 H) 3.72 (s, 3 H) 2.23 (s, 6 H) 1.26 (s, 9 H); MS (ES) *m/z* 371 [M+1]⁺.

Example 4i**5-(3-Bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**

- 5 Magnesium turnings (0.820 g, 33.74 mmol) were stirred under Ar(g) for 10min. LiCl 0.5M in THF (67.5 mL, 33.74 mmol) was added followed by DIBAL-H (1M in THF) (0.116 mL, 0.12 mmol) and the mixture was stirred for 5 min. 1-Bromo-3-iodobenzene (9.22 g, 32.57 mmol) in THF (2 mL) was added in one portion and stirring was continued for 1.5h. The mixture was transferred to a cooled solution of *N*-((3-cyanopyrazin-2-yl)(4-methoxy-3,5-
- 10 dimethylphenyl)methylene)-2-methylpropane-2-sulfinamide (8.62 g, 23.27 mmol) in THF (22 mL) at -20 °C. The resulting mixture was stirred for another 10 min before the cooling bath was removed and the reaction mixture was allowed to reach rt. The mixture was stirred for another 1h at rt. MeOH(10mL) was added and the reaction mixture was treated with HCl in MeOH (37.2 mL, 46.54 mmol) for 1h. NaHCO₃ (sat) was added and the
- 15 mixture was concentrated to remove most of the organic solvents. The residue was extracted with EtOAc, the organic phase was washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. Chromatography of the residue using 0 - 2% MeOH (containing approx. 3.5 N NH₃) in DCM gave 7.83g (79%) of the title compound.
- 20 ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.73 - 8.75 (m, 1 H) 8.70 - 8.73 (m, 1 H) 7.69 (t, 1 H) 7.57 - 7.62 (m, 1 H) 7.39 - 7.43 (m, 1 H) 7.26 (t, 1 H) 7.15 (s, 2 H) 7.11 (br. s., 2 H) 3.58 (s, 3 H) 2.13 (s, 6 H); MS (ES) *m/z* 423, 425 [M+1]⁺.


Example 5i**3-(3-Bromobenzoyl)pyrazine-2-carbonitrile**

Magnesium turnings (1.142 g, 47.00 mmol) were stirred under Ar(g) for 10min and LiCl 0.5M in THF (100 mL, 50.05 mmol) was added followed by DIBAL-H (1M in THF) (0.218 mL, 0.22 mmol). The mixture was stirred for 5 min and 1,3-dibromobenzene (10.78 g, 45.70 mmol) was added in one portion and stirred o.n.. The mixture was transferred over
5 30 min to methyl 3-cyanopyrazine-2-carboxylate (7.1 g, 43.52 mmol) in THF (60 mL) at -78 °C. The mixture was stirred at this temperature for 1 h. The cooling bath was removed and after 30 min, water (40 mL) was added. Most of the THF was evaporated and NH₄Cl (sat) was added. The mixture was extracted with EtOAc. The organic phase was washed with brine, dried over MgSO₄ and concentrated. Chromatography of the residue using 0 -
10 30% EtOAc in *n*-heptane as eluent gave 7.63 g (61%) of the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.09 - 9.10 (m, 1 H) 9.05 - 9.06 (m, 1 H) 8.12 (t, 1 H) 7.93 - 8.00 (m, 2 H) 7.57 (t, 1 H); MS (CI) *m/z* 288, 290 [M+1]⁺.


Example 6i

15 ***N*-((3-Bromophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide**



Titanium(IV) ethoxide (13.13 g, 57.58 mmol) was dissolved in THF (60 mL). 3-(3-bromobenzoyl)pyrazine-2-carbonitrile (7.54 g, 26.17 mmol) was added followed by 2-methyl-2-propanesulfinamide (4.12 g, 34.02 mmol). The mixture was heated to 50 °C for
20 72 h and subsequently cooled to rt. MeOH (20mL), EtOAc (100 mL) and NaHCO₃ (sat) (2 mL) were added and the mixture was stirred for 10 min at rt. Silica was added and the solvents were removed under reduced pressure. Chromatography of the residue using 0 -
30% EtOAc in *n*-heptane as eluent gave 4.8 g (47%) of the title compound.


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 9.02 - 9.08 (m, 1 H) 8.95 - 8.98 (m, 1 H) 7.81 -
25 7.90 (m, 2 H) 7.61 - 7.67 (m, 1 H) 7.49 (t, 1 H) 1.28 (s, 9 H); MS (ES) *m/z* 391, 393 [M+1]⁺.

Example 7i**5-(3-Bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**

- 5 Magnesium turnings (0.130 g, 5.37 mmol) were stirred under Ar(g) for 10 min and LiCl 0.5M in THF (7.51 mL, 3.76 mmol) was added followed by DIBAL-H (1M in THF) (0.027 mL, 0.03 mmol). The mixture was stirred for 5 min and 5-bromo-2-methoxy-1,3-dimethylbenzene (0.693 g, 3.22 mmol) in THF (1 mL) was added in one portion and stirring was continued o.n. The mixture was transferred to *N*-((3-bromophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide (1.05 g, 2.68 mmol) in THF (5 mL) at rt and the resulting mixture was stirred for 2 h. MeOH (4mL) was added and the mixture was treated with HCl in MeOH (4.29 mL, 5.37 mmol) for 3 h. NaHCO₃ (sat) was added and the mixture was extracted with EtOAc. The organic phases were washed with brine, dried over MgSO₄ and concentrated. Chromatography using 0 - 2% MeOH (containing approx. 3.5 N NH₃) in DCM as eluent gave 0.41 g (36%) of the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.73 - 8.75 (m, 1 H) 8.70 - 8.73 (m, 1 H) 7.69 (t, 1 H) 7.57 - 7.62 (m, 1 H) 7.39 - 7.43 (m, 1 H) 7.26 (t, 1 H) 7.15 (s, 2 H) 7.11 (br. s., 2 H) 3.58 (s, 3 H) 2.13 (s, 6 H); MS (ES) *m/z* 423, 425 [M+1]⁺.

20

Example 8i**5-(3-Bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**


Chiral separation of 5-(3-bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine (200mg) in EtOH(10mL) into its isomers was performed on a Chiralpak AD column 50*300 mm, 20μm, using 20% EtOH+0.1%DEA / 80% *n*-heptane as mobile phase at a flowrate of 120mL/min, to yield:

5 Isomer 1, with unknown absolute configuration, the first to elute (70 mg, 35% yield): ¹H NMR (500 MHz, DMSO-*d*₆) ppm 8.74 (d, 1 H) 8.72 (d, 1 H) 7.70 (t, 1 H) 7.60 (m, 1 H) 7.41 (m, 1 H) 7.26 (t, 1 H) 7.15 (s, 2 H) 7.10 (br. s., 2 H) 3.58 (s, 3 H) 2.13 (s, 6 H); MS (ES) *m/z* 423, 425 [M+1]⁺; and

Isomer 2, with unknown absolute configuration, the second to elute (72 mg, 36% yield),:
10 ¹H NMR (500 MHz, DMSO-*d*₆) ppm 8.74 (d, 1 H) 8.72 (d, 1 H) 7.70 (t, 1 H) 7.60 (m, 1 H) 7.41 (m, 1 H) 7.26 (t, 1 H) 7.15 (s, 2 H) 7.10 (br. s., 2 H) 3.58 (s, 3 H) 2.13 (s, 6 H); MS (ES) *m/z* 423, 425 [M+1]⁺.

Example 9i

15 5-Bromo-1-chloro-2-methoxy-3-methylbenzene




4-Bromo-2-chloro-6-methylphenol (2.97 g, 13.41 mmol) and potassium carbonate (2.78 g, 20.11 mmol) was slurried in DMF (10 mL) for 1 min before methyl iodide (1.090 mL, 17.43 mmol) was added. The mixture was stirred o.n. at rt. Water was added and the
20 mixture was extracted with Et₂O. The organic phases were washed with water, brine, dried over MgSO₄ and concentrated to give 2.96 g (94%) of the title compound.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.54 - 7.58 (m, 1 H) 7.42 - 7.47 (m, 1 H) 3.73 (s, 3 H) 2.26 (s, 3 H); MS (CI) *m/z* 235, 237 [M+1]⁺.

25 Example 10i

5-(3-Bromophenyl)-5-(3-chloro-4-methoxy-5-methylphenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine




The title compound was synthesized as described for Example 7i in 78% yield starting from *N*-((3-bromophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfonamide (375mg, 0.96mmol) and 5-bromo-1-chloro-2-methoxy-3-methylbenzene (293mg, 1.25mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 - 8.79 (m, 1 H) 8.73 - 8.76 (m, 1 H) 7.69 (t, 1 H) 7.58 - 7.62 (m, 1 H) 7.40 - 7.46 (m, 2 H) 7.35 - 7.37 (m, 1 H) 7.28 (t, 1 H) 7.23 (br. s., 2 H) 3.68 (s, 3 H) 2.20 (s, 3 H); MS (ES) *m/z* 443, 445 [M+1]⁺.

Example 11i

3-(3-Fluoro-4-methoxybenzoyl)pyrazine-2-carbonitrile




(3-Fluoro-4-methoxyphenyl)magnesium bromide (49.0 mL, 24.52 mmol) was added dropwise over 20min to methyl 3-cyanopyrazine-2-carboxylate (4 g, 24.52 mmol) in THF (45 mL) at -78 °C under nitrogen atmosphere. The mixture was kept at -78 °C for 15 min. NH₄Cl (sat) (5mL) was added and the reaction mixture was allowed to reach rt. Water (5mL) and brine were added, and the mixture was extracted with EtOAc. The organic phases were combined, dried over MgSO₄ and concentrated. Chromatography on silica using 0 - 80% EtOAc in heptane as eluent gave 5.19 g (82%) of the title compound.

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 9.08 (d, 1 H) 9.05 (d, 1 H) 7.83 - 7.89 (m, 2 H) 7.37 (t, 1 H) 3.98 (s, 3 H); MS (CI) *m/z* 258 [M+1]⁺.

Example 12i

N-((3-Cyanopyrazin-2-yl)(3-fluoro-4-methoxyphenyl)methylene)-2-methylpropane-2-sulfonamide




The title compound was synthesized as described for Example 6i in 60% yield starting from 3-(3-fluoro-4-methoxybenzoyl)pyrazine-2-carbonitrile (5.19 g, 20.18 mmol).

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 9.01 - 9.06 (m, 1 H) 8.95 (d, 1 H) 7.61 (d, 1 H)
 5 7.34 - 7.38 (m, 1 H) 7.25 (t, 1 H) 3.93 (s, 3 H) 1.26 (s, 9 H); MS (ES) *m/z* 361 [M+1]⁺.

Example 13i

5-(3-Chlorophenyl)-5-(3-fluoro-4-methoxyphenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine




10 (3-Chlorophenyl)magnesium bromide (3.66 mL, 1.83 mmol) was added dropwise to *N*-((3-cyanopyrazin-2-yl)(3-fluoro-4-methoxyphenyl)methylene)-2-methylpropane-2-sulfonamide (0.6 g, 1.66 mmol) in THF (11 mL) at rt and the mixture was stirred for 1.5 h. MeOH (5mL) was added followed by HCl in MeOH (2.66 mL, 3.33 mmol) and stirring was continued for another 3 h. NaHCO₃ (sat) was added and the resulting mixture was
 15 extracted with EtOAc. The organic phases were washed with brine, dried over MgSO₄ and concentrated. Chromatography of the residue using 0 - 2% MeOH (containing approx. 3.5 N NH₃) in DCM as eluent gave 0.53 g (86%) of the title compound.

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.73 - 8.75 (m, 2 H) 7.50 - 7.54 (m, 2 H) 7.26 - 7.35 (m, 4 H) 7.16 (br. s., 2 H) 7.10 (t, 1 H) 3.78 (s, 3 H); MS (ES) *m/z* 369 [M+1]⁺.

Example 14i

3-(3-Chlorobenzoyl)pyrazine-2-carbonitrile




The title compound was synthesized as described for Example 11i in 69% yield starting from methyl 3-cyanopyrazine-2-carboxylate (3.8 g, 23.29 mmol) and (3-chlorophenyl)magnesium bromide (49.8 mL, 24.92 mmol).

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 9.10 (d, 1 H) 9.06 (d, 1 H) 8.00 (t, 1 H) 7.93 - 7.97 (m, 1 H) 7.81 - 7.85 (m, 1 H) 7.64 (t, 1 H); MS (CI) *m/z* 244 [M+1]⁺.

Example 15i

***N*-((3-Chlorophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfonamide**




The title compound was synthesized as described for Example 6i in 43% yield starting from 3-(3-chlorobenzoyl)pyrazine-2-carbonitrile (3.9 g, 16.01 mmol).

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 9.02 - 9.07 (m, 1 H) 8.96 (d, 1 H) 7.67 - 7.76 (m, 2 H) 7.52 - 7.64 (m, 2 H) 1.29 (s, 9 H); MS (ES) *m/z* 347 [M+1]⁺.

Example 16i

5-(3-Chlorophenyl)-5-(3-cyclopropyl-4-methoxyphenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine




The title compound was synthesized as described for Example 7i in 71% yield starting

from 4-bromo-2-cyclopropyl-1-methoxybenzene (400 mg, 1.76 mmol) and *N*-((3-chlorophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfonamide (611 mg, 1.76 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.70 - 8.74 (m, 2 H) 7.47 - 7.51 (m, 2 H) 7.25 - 7.33 (m, 3 H) 7.11 (br. s., 2 H) 7.02 (d, 1 H) 6.84 (d, 1 H) 3.74 (s, 3 H) 1.95 - 2.04 (m, 1 H) 0.81 - 0.88 (m, 2 H) 0.37 - 0.44 (m, 2 H); MS (ES) *m/z* 391 [M+1]⁺.

5 **Example 17i**

5-(3-Chlorophenyl)-5-(3,5-difluoro-4-methoxyphenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine




The title compound was synthesized as described for Example 7i in 82% yield starting
10 from 5-bromo-1,3-difluoro-2-methoxybenzene (347 mg, 1.56 mmol) and *N*-((3-chlorophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide (450mg, 1.30 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.75 - 8.79 (m, 2 H) 7.52 - 7.56 (m, 2 H) 7.22 - 7.39 (m, 6 H) 3.87 (s, 3 H); MS (ES) *m/z* 387 [M+1]⁺.

15

Example 18i


5-(3-Bromophenyl)-5-(2-cyclopropylpyridin-4-yl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine



The title compound was synthesized as described for Example 7i in 74% yield starting
20 from 4-bromo-2-cyclopropylpyridine (145 mg, 0.73 mmol) and *N*-((3-bromophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide (220 mg, 0.56 mmol).


¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.76 - 8.78 (m, 2 H) 8.27 - 8.31 (m, 1 H) 7.73 (t, 1 H) 7.60 - 7.64 (m, 1 H) 7.44 - 7.48 (m, 1 H) 7.37 - 7.40 (m, 1 H) 7.20 - 7.33 (m, 4 H) 1.96 - 2.06 (m, 1 H) 0.82 - 0.89 (m, 4 H); MS (ES) *m/z* 406, 408 [M+1]⁺.

25

Example 19i**2-(Benzyloxy)-4-bromopyridine**

4-Bromo-2-fluoropyridine (5.28 g, 30 mmol) and benzyl alcohol (3.24 g, 30.00 mmol) were dissolved in dry THF (50 mL) under an atmosphere of argon. The solution was cooled with an external ice/water bath and held at 0 °C. Potassium *tert*-butoxide (3.37 g, 30.00 mmol) was added in portions (approx. 100 mg each) under efficient stirring over a period of 20 min. Stirring at 0 °C was continued for 60 min, whereafter the cooling bath was removed and the mixture was stirred at rt for 30 min. Water (5 mL) was added to the reaction mixture and most of the THF was evaporated under reduced pressure. The remaining mixture was partitioned between pentane (75 mL) and water (50 mL). The organic phase was separated, washed with water (2x25 mL), dried over MgSO₄ and the solvents removed *in vacuo* to afford 7.86 g (99%) of the title compound.

¹H NMR (500 MHz, DMSO-*d*₆) δ 8.10 (d, 1H) 7.44 (d, 2H) 7.38 (t, 2H) 7.33 (t, 1H) 7.25 (d, 1H) 7.20 (s, 1H) 5.36 (s, 2H).


Example 20i**5-(2-(Benzyloxy)pyridin-4-yl)-5-(3-bromophenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**

The title compound was synthesized as described for Example 7i in 74% yield starting from 2-(benzyloxy)-4-bromopyridine (225 mg, 0.85 mmol) and *N*-((3-bromophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide (256 mg, 0.65 mmol).

^1H NMR (400 MHz, DMSO- d_6) δ ppm 8.75 - 8.77 (m, 2 H) 8.07 - 8.10 (m, 1 H) 7.75 (t, 1 H) 7.61 - 7.66 (m, 1 H) 7.27 - 7.42 (m, 10 H) 7.09 - 7.14 (m, 1 H) 5.28 (s, 2 H); MS (ES) m/z 472, 474 $[\text{M}+1]^+$.

5 **Example 21i**

4-Bromo-2-cyclopropylpyridine



To a solution of 2,4-dibromopyridine (3 g, 12.66 mmol) in dry tetrahydrofuran (10 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.435 g, 0.38 mmol).


10 Cyclopropylzinc(II) bromide, 0.5M in tetrahydrofuran (30.1 mL, 15.05 mmol) was added over a period of 10 minutes. The reaction mixture was stirred at rt for 80 min. Additional cyclopropylzinc(II) bromide, 0.5M in tetrahydrofuran (7.52 mL, 3.76 mmol), was added and the reaction mixture was stirred for another 40 min before it was poured into saturated aqueous NaHCO_3 (100 mL) and diluted with EtOAc (100 mL). The layers were separated and the aqueous layer was extracted with EtOAc (50 mL). The organics were combined, 15 dried over Na_2SO_4 , filtered and evaporated at reduced pressure. The crude was purified by flash chromatography on silica gel to give 2.12 g (85%) of the title compound.

^1H NMR (400 MHz, CDCl_3) δ ppm 8.25 (d, 1 H) 7.33 (d, 1 H) 7.21 (dd, 1 H) 1.93 - 2.04 (m, 1 H) 0.98 - 1.08 (m, 4 H); MS (CI) m/z 198, 200 $[\text{M}+1]^+$.

20

Example 22i

2-Fluoro-6-methylphenol




3-Fluoro-2-hydroxybenzaldehyde (2.5 g, 17.84 mmol) was dissolved in MeOH (200 mL). 25 Pd/C 10% (0.25 g, 2.35 mmol) was added under a stream of nitrogen. The mixture was hydrogenated at 50 psi and 50 °C for 4 days. Hydrochloric acid (2 mL, conc) was added followed by Pd/C (10%) (0.25 g, 2.35 mmol). The mixture was hydrogenated at 50 psi and

50 °C over night. The mixture was filtered through a pad of diatomaceous earth and the filter was washed with methanol. The solvents were evaporated to give 0.9 g (40%) of the title compound.

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 2.15 (s, 3 H) 6.62 - 6.70 (m, 1 H) 6.87 (d, 1 H) 6.93 (t, 1 H) 9.28 (br. s., 1 H).

Example 23i

4-Bromo-2-fluoro-6-methylphenol




2-Fluoro-6-methylphenol (0.95 g, 7.53 mmol) was dissolved in acetic acid (15 mL). The mixture was cooled on an ice-water bath. *N*-bromosuccinimide (1.408 g, 7.91 mmol) was added in portions and the mixture was allowed to reach rt and was stirred at rt for 3 h. The mixture was concentrated under reduced pressure and the residue was diluted with dichloromethane (100 ml). The organic phase was washed with NaHCO₃ (sat, aq) containing Na₂S₂O₃. The aqueous phase was extracted with dichloromethane. The combined organic phases were dried over MgSO₄ and evaporated to give 1.36 g (88%) of the title compound.

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 2.16 (s, 3 H) 7.12 (s, 1 H) 7.25 (dd, 1 H) 9.66 (br. s., 1 H).

Example 24i

5-Bromo-1-fluoro-2-methoxy-3-methylbenzene




4-Bromo-2-fluoro-6-methylphenol (0.34 g, 1.66 mmol) was dissolved in acetonitrile (10 mL). Potassium carbonate (0.458 g, 3.32 mmol) was added to the solution, followed by iodomethane (0.207 mL, 3.32 mmol). The mixture was stirred at rt for 60 h. The reaction mixture was diluted with dichloromethane and washed with brine. The aqueous phase was

extracted with dichloromethane. The combined organic phases were dried (MgSO₄) and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica eluting with an increasing gradient of EtOAc in heptane to give 0.15 g (41%) of the title compound.

¹H NMR (500 MHz, CDCl₃) δ ppm 2.25 (s, 3 H) 3.89 (d, 3 H) 7.07 - 7.12 (m, 2 H).

Example 25i

5-(3-Bromophenyl)-5-(3-fluoro-4-methoxy-5-methylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine




The title compound was synthesized as described for Example 7i in 68% yield starting from 5-bromo-1-fluoro-2-methoxy-3-methylbenzene (154 mg, 0.70 mmol) and *N*-((3-bromophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide (250mg, 0.64 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.73 - 8.77 (m, 2 H) 7.69 (t, 1 H) 7.58 - 7.61 (m, 1 H) 7.42 - 7.46 (m, 1 H) 7.27 (t, 1 H) 7.13 - 7.24 (m, 4 H) 3.75 (s, 3 H) 2.16 (s, 3 H); MS (ES) *m/z* 427, 429 [M+1]⁺.


Example 26i

5-Bromo-2-ethoxy-1,3-dimethylbenzene




The title compound was synthesized as described for Example 9i in 95% yield starting from iodoethane (2.78 mL, 34.82 mmol) and 4-bromo-2,6-dimethylphenol (3.5 g, 17.41 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.21 - 7.23 (m, 2 H) 3.78 (q, 2 H) 2.19 (s, 6 H) 1.31 (t, 3 H).

Example 27i**5-(3-Bromophenyl)-5-(4-ethoxy-3,5-dimethylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**


The title compound was synthesized as described for Example 7i in 40% yield starting from 5-bromo-2-ethoxy-1,3-dimethylbenzene (221 mg, 0.96 mmol) and *N*-((3-bromophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide (290 mg, 0.74 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.73 - 8.75 (m, 1 H) 8.70 - 8.72 (m, 1 H) 7.70 (t, 1 H) 7.59 - 7.62 (m, 1 H) 7.39 - 7.43 (m, 1 H) 7.26 (t, 1 H) 7.14 (s, 2 H) 7.10 (br. s., 2 H) 3.72 (q, 2 H) 2.13 (s, 6 H) 1.28 (t, 3 H); MS (ES) *m/z* 437, 439 [M+1]⁺.

Example 28i**5-Bromo-1-fluoro-3-methyl-2-(vinylloxy)benzene**


4-Bromo-2-fluoro-6-methylphenol (2 g, 9.75 mmol), vinyl acetate (1.8 mL, 19.51 mmol), sodium carbonate (0.620 g, 5.85 mmol) and chloro(1,5-cyclooctadiene)iridium(I) dimer (0.066 g, 0.10 mmol) in toluene (8 mL) were heated to 100 °C under Ar(g) for 3 h. After cooling to rt, the mixture was filtered through a plug of silica eluting with *n*-heptane. Evaporation of solvents gave 1.48 g (66%) of the title compound which was used without further purification in the next step.

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.49 - 7.54 (m, 1 H) 7.39 (s, 1 H) 6.73 - 6.79 (m, 1 H) 4.28 - 4.33 (m, 1 H) 4.18 - 4.24 (m, 1 H) 2.19 (s, 3 H); MS (CI) *m/z* 231, 233 [M+1]⁺.

Example 29i**5-Bromo-2-cyclopropoxy-1-fluoro-3-methylbenzene**


5-Bromo-1-fluoro-3-methyl-2-(vinylloxy)benzene (1.48 g, 6.41 mmol) was dissolved in 1,2-dichloroethane (20 mL) and chloriodomethane (1.493 mL, 20.50 mmol) at 0 °C under an atmosphere of argon. Diethylzinc (10.25 mL, 10.25 mmol) was added dropwise. After 10 min the mixture was warmed up to rt and stirred for 1 h. Additional chloriodomethane (0.744 mL, 10.25 mmol) and diethylzinc (5.12 mL, 5.12 mmol) were added and the mixture was stirred for 2 h. NH₄Cl (sat) (20 mL) and NH₄OH (conc.) (10 mL) were added and the aqueous phase was extracted with DCM. The organic phases were combined, dried over MgSO₄, filtered and concentrated to give 1.52 g (97%) of the title compound.

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 7.39 - 7.44 (m, 1 H) 7.25 - 7.28 (m, 1 H) 4.12 (tq, 1 H) 2.17 (s, 3 H) 0.69 - 0.74 (m, 2 H) 0.56 - 0.62 (m, 2 H); MS (CI) *m/z* 245, 247 [M+1]⁺.

Example 30i**5-(3-Bromophenyl)-5-(4-cyclopropoxy-3-fluoro-5-methylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**

The title compound was synthesized as described for Example 7i in 53% yield starting from 5-bromo-2-cyclopropoxy-1-fluoro-3-methylbenzene (191 mg, 0.78 mmol) and *N*-((3-bromophenyl)(3-cyanopyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide (235 mg, 0.60 mmol).


¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.73 - 8.78 (m, 2 H) 7.71 (t, 1 H) 7.59 - 7.64 (m, 1 H) 7.41 - 7.46 (m, 1 H) 7.28 (t, 1 H) 7.14 - 7.23 (m, 4 H) 4.02 - 4.07 (m, 1 H) 2.11 (s, 3 H) 0.65 - 0.70 (m, 2 H) 0.50 - 0.57 (m, 2 H); MS (ES) *m/z* 453, 455 [M+1]⁺.

Example 31i**1-Allyloxy-2-bromo-benzene**

5 See also e.g. *European Journal of Organic Chemistry*, 2008, (1), 196-213; *Bioorganic & Medicinal Chemistry* 2008, 16(2), 762-770.

NaH (60 % suspension in mineral oil, 2.4 g, 60.0 mmol) was added in small portions to a solution of 2-bromo-phenol (10.0 g, 57.8 mmol) in dry DMF (100 mL) at 0 °C. The reaction mixture was stirred vigorously for 1 hour at 0°C and allyl bromide (5.8 mL, 68.0
10 mmol) was added slowly to the reaction mixture. The reaction mixture was allowed to warm to room temperature and stirred for 1 hour. Ice-cold saturated NH₄Cl solution (100 mL) was then added and the mixture was extracted with Et₂O (3 x 150 mL). The combined extracts were washed with water, dried over MgSO₄, filtered and concentrated under reduced pressure. The oily residue was purified by flash column chromatography using 5%
15 EtOAc in hexane, followed by careful evaporation of the solvent *in vacuo* at low temperature (to avoid loss of material), to afford the title compound (10.5 g, 85%).
¹H NMR (400 MHz, CDCl₃) δ ppm 7.48 - 7.57 (m, 1 H), 7.23 - 7.28 (m, 1 H), 6.76 - 6.95 (m, 2 H), 5.98 - 6.14 (m, 1 H), 5.41 - 5.54 (m, 1 H), 5.31 (dd, 1 H), 4.62 (d, 2 H).

20 **Example 32i**

2-Cyclopropyl-phenol

See also e.g. *Bioorganic & Medicinal Chemistry* 2008, 16(2), 762-770.


tert-BuLi (1.7 M in pentane, 77.0 mL, 130.9 mmol) was added dropwise to a solution of 1-allyloxy-2-bromo-benzene (14.0 g, 65.7 mmol) in anhydrous Et₂O (300 mL) over a period
25 of 1 hour at -78 °C. The reaction mixture was stirred for 1 hour at -78 °C and TMEDA (22.6 mL, 150.7 mmol) was then added slowly. The reaction mixture was allowed to warm to room temperature and stirred overnight. Ice-cold saturated NH₄Cl solution (100 mL)

was added and the resulting mixture was extracted with EtOAc (3 x 200 mL). The combined extracts were dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography using 10% EtOAc in hexane to afford the title compound followed by careful evaporation of the solvent *in vacuo* at low temperature (to avoid loss of material), to afford the title compound (8.0 g, 90%).

¹H NMR (400 MHz, CDCl₃) δ ppm 7.10 - 7.16 (m, 1 H), 7.08 (d, 1 H), 6.82 - 6.88 (m, 2 H), 5.46 (br. s., 1 H), 1.74 - 1.86 (m, 1 H), 0.91 - 1.02 (m, 2 H), 0.59 - 0.69 (m, 2 H).

Example 33i

4-Bromo-2-cyclopropyl-phenol




Bromine (3.06 mL, 59.7 mmol) was added dropwise to a solution of 2-cyclopropyl-phenol (8.0 g, 59.7 mmol) in CH₂Cl₂ (300 mL) at 0 °C. The reaction mixture was stirred for 1 h at 0 °C and then quenched using saturated NaHCO₃ solution. The phases were separated and the aqueous layer was further extracted with CH₂Cl₂ (3 x 50 mL). The combined extracts were dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography using 10% EtOAc in hexane to afford the title compound (12.1 g, 95%).

¹H NMR (400 MHz, CDCl₃) δ ppm 7.21 (dd, 1 H), 7.16 (d, 1 H), 6.74 (d, 1 H), 5.58 (s, 1 H), 1.76 - 1.85 (m, 1 H), 0.95 - 1.02 (m, 2 H), 0.61 - 0.69 (m, 2 H).

Example 34i

4-Bromo-2-cyclopropyl-1-methoxy-benzene




K₂CO₃ (8.7 g, 62.9 mmol) was added to a solution of 4-bromo-2-cyclopropyl-phenol (9.0 g, 42.3 mmol) in DMF (40 mL) at 0 °C, followed by addition of MeI (3.7 mL, 59.4 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The

reaction mixture was filtered, diluted with H₂O (100 mL) and extracted with Et₂O (3 x 50 mL). The combined extracts were dried over MgSO₄, filtered and concentrated under reduced pressure. The oily residue was purified by flash column chromatography using 3% EtOAc in hexane to give the title compound (8.0 g, 84%).

5 ¹H NMR (400 MHz, CDCl₃) δ ppm 7.21 (dd, 1 H), 6.91 (d, 1 H), 6.70 (d, 1 H), 3.84 (s, 3 H), 2.13 (tt, 1 H), 0.83 - 1.03 (m, 2 H), 0.53 - 0.70 (m, 2 H); MS (ES) *m/z* 227, 229 [M+1]⁺.

Example 35i

10 2-Allyloxy-1-bromo-3-methyl-benzene




A solution of 2-bromo-6-methylphenol (20.0 g, 106.9 mmol) in anhydrous DMF (200 mL) was cooled to 0 °C and NaH (60 % suspension in mineral oil, 5.1 g, 128.3 mmol) was added in small portions. The reaction mixture was stirred for 5 minutes and allyl bromide
15 (10.9 mL, 128.3 mmol) was added dropwise. The resulting mixture was allowed to warm to room temperature and stirred overnight. Water (200 mL) was then added and the mixture extracted with diethyl ether (2 x 300 mL). The combined extracts were washed with water, brine, dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash column chromatography using 5% ethyl acetate in
20 hexanes to afford the title compound (24.5 g, 100%).

¹H NMR (400 MHz, CDCl₃) δ ppm 7.40 (dd, 1 H), 7.13 (d, 1 H), 6.90 (t, 1 H), 6.20-6.10 (m, 1 H), 5.47 (m, 1 H), 5.30 (m, 1 H), 4.45 (m, 2 H), 2.32 (s, 3 H).

Example 36i

25 2-Cyclopropyl-6-methyl-phenol




tert-BuLi (1.7 M in pentane, 64.0 mL, 108.3 mmol) was added dropwise to a solution of 2-allyloxy-1-bromo-3-methyl-benzene (12.0 g, 52.84 mmol) in anhydrous diethyl ether (300

mL) at -78 °C. The resulting mixture was stirred for 30 minutes at -78 °C and TMEDA (17.5 mL, 116.25 mmol) was added dropwise. The reaction mixture was stirred at -78 °C for an additional 45 minutes, then allowed to warm to room temperature and stirred overnight. Water (300 mL) was added and the mixture was extracted with ethyl acetate (2 x 300 mL). The combined extracts were washed with 2 N HCl (150 mL), brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash column chromatography using 10% ethyl acetate in hexanes to afford 7.0 g (89%) of the title compound.

¹H NMR (400 MHz, CDCl₃) δ ppm 7.01 (d, 1 H), 6.96 (d, 1 H), 6.76 (t, 1 H), 5.55 (s, 1 H), 2.26 (s, 3 H), 1.79-1.73 (m, 1 H), 0.99-0.94 (m, 2 H), 0.65-0.62 (m, 2 H).

Example 37i

4-Bromo-2-cyclopropyl-6-methyl-phenol




Bromine (1.6 mL, 31.7 mmol) was added dropwise to a solution of 2-cyclopropyl-6-methyl-phenol (4.7 g, 31.71 mmol) in dichloromethane (50 mL) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 1 h. The mixture was diluted with dichloromethane (50 mL) and washed with saturated NaHCO₃ solution, brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash column chromatography using 10% ethyl acetate in hexanes to afford 5.5 g (76%) of the title compound.

¹H NMR (400 MHz, CDCl₃) δ ppm 7.13 (d, 1 H), 7.05 (d, 1 H), 5.50 (s, 1 H), 2.22 (s, 3 H), 1.76-1.72 (m, 1 H), 1.00-0.96 (m, 2 H), 0.65-0.62 (m, 2 H).

Example 38i

5-Bromo-1-cyclopropyl-2-methoxy-3-methyl-benzene




K₂CO₃ (3.2 g, 23.2 mmol) was added to a solution of 4-bromo-2-cyclopropyl-6-methylphenol (3.0 g, 13.2 mmol) in DMF (30 mL) at 0 °C and the resulting mixture was stirred vigorously for 30 minutes. MeI (0.9 mL, 14.45 mmol) was then added at 0 °C, and the reaction mixture was allowed to warm to room temperature and stirred for 3 hours. The mixture was filtered, diluted with H₂O (50 mL) and extracted with Et₂O (3 x 50 mL). The combined extracts were dried over MgSO₄, filtered and concentrated under reduced pressure. The oily residue was purified by flash column chromatography using 5% EtOAc in hexane to afford the title compound (2.9 g, 93%).

¹H NMR (400 MHz, CDCl₃) δ ppm 7.10 (d, 1 H), 6.74 (d, 1 H), 3.78 (s, 3 H), 2.26 (s, 3 H), 2.11 - 2.19 (m, 1 H), 0.95 - 1.03 (m, 2 H), 0.63 - 0.69 (m, 2 H).

Example 39i

7-(3-Chloro-phenyl)-7-(3-cyclopropyl-4-methoxy-5-methyl-phenyl)-7H-pyrrolo[3,4-b]pyrazin-5-ylamine




LiCl (0.5M in THF, 6.2 mL, 3.1 mmol) was added to magnesium turnings (151 mg, 6.2 mmol) under nitrogen and the mixture was stirred for 15 minutes at room temperature. DIBAL-H (1M in THF, 0.02 mL, 0.02 mmol) was added to the above solution and the stirring at room temperature was continued for 5 minutes. The mixture was then warmed to 35 °C and a solution of 5-bromo-1-cyclopropyl-2-methoxy-3-methyl-benzene (500 mg, 2.1 mmol) in dry THF (30 mL) was added slowly. The reaction mixture was stirred for an additional 10 minutes at 35 °C, cooled to 0 °C and added to a solution of 2-methylpropane-2-sulfinic acid (3-chloro-phenyl)-(3-cyano-pyrazin-2-yl)-methyleamide (574 mg, 1.7 mmol) in dry THF (10 mL). The reaction mixture was stirred at room temperature for 4 h. Methanol (5 mL) and HCl (1.25 M in MeOH, 4.1 mL, 5.2 mmol) were added and the reaction mixture was stirred for 2 h at room temperature. The reaction mixture was quenched using saturated NaHCO₃ solution and extracted with EtOAc (3 x 50 mL). The combined extracts were dried over MgSO₄, filtered and concentrated *in vacuo*. The residue

was purified by flash column chromatography using a gradient of 0-2% MeOH (2M NH₃) in DCM to afford the title compound (350 mg, 52%).

¹H NMR (400 MHz, CDCl₃) δ ppm 8.60 (d, 1 H), 8.53 (d, 1 H), 7.53 (s, 1 H), 7.42 - 7.47 (m, 1 H), 7.19 (d, 2 H), 7.15 (d, 1 H), 6.86 (d, 1 H), 5.32 (br. s., 2 H), 3.76 (s, 3 H), 2.23 (s, 3 H), 2.09 - 2.16 (m, 1 H), 0.90 (m, 2 H), 0.58 (m, 2 H); MS (ES) *m/z* 405 [M+1]⁺.

Example 40i

(R)-N-((3-Cyanopyrazin-2-yl)(4-methoxy-3,5-dimethylphenyl)methylene)-2-methylpropane-2-sulfinamide




3-(4-methoxy-3,5-dimethylbenzoyl)pyrazine-2-carbonitrile (1.35 g, 5.05 mmol), and (R)-(+)-2-methyl-2-propanesulfinamide (1.102 g, 9.09 mmol) was dissolved in THF (9 mL) and titanium(IV) ethoxide (1.903 mL, 9.09 mmol) was added. The mixture was heated to 120 °C with MW for 40 min. The mixture was transferred to a round-bottom flask, EtOAc, (approx 10 mL) MeOH (approx 10 mL) and water (12 mL) was added under stirring and after 5 min silica was added. The mixture was concentrated to dryness and applied on a silica column. Chromatography on silica using 0-30% EtOAc in *n*-heptane as eluent, gave 1.07g (57% yield) of the title compound.

¹H NMR (500 MHz, DMSO-*d*₆) ppm 9.03 (br. s., 1 H) 8.94 (d, 1 H) 7.31 (s, 2 H) 3.72 (s, 3 H) 2.23 (s, 6 H) 1.26 (s, 9 H). MS (ES) *m/z* 371 [M+1]⁺.

Example 41i

(R)-5-(3-Bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5H-pyrrolo[3,4-b]pyrazin-7-amine




The title compound was synthesized as described for Example 4i in 70% yield starting from 1,3-dibromobenzene (0.886 g, 3.75 mmol) and (R)-N-((3-cyanopyrazin-2-yl)(4-methoxy-3,5-dimethylphenyl)methylene)-2-methylpropane-2-sulfinamide (1.07g, 2.89 mmol).

¹H NMR (500 MHz, DMSO-*d*₆) ppm 8.74 (d, 1 H) 8.72 (d, 1 H) 7.70 (t, 1 H) 7.58 - 7.61 (m, 1 H) 7.40 - 7.43 (m, 1 H) 7.26 (t, 1 H) 7.15 (s, 2 H) 7.10 (br. s., 2 H) 3.58 (s, 3 H) 2.13 (s, 6 H); MS (ES) *m/z* 423, 425 [M+1]⁺; Chiral HPLC analysis; 99.5% enantiomeric purity (15% EtOH+DEA 85% n-heptane on Chiralpak AD-H 4.6*250 mm 5μm at 3mL/min) using 5-(3-bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine (Example 8i) as reference. The title compound corresponds to Isomer 2 of the reference.

Example 1

5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine




Pyrimidin-5-ylboronic acid (1.030 g, 8.32 mmol), 5-(3-bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine (1.6 g, 3.78 mmol), cesium carbonate (3.69 g, 11.34 mmol) and dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.247 g, 0.30 mmol) were dissolved in DME:EtOH:Water (6:3:1, 12 mL) and irradiated in a microwave reactor for 25 min at 140 °C. EtOAc, water (10 mL) and brine were added. The organic phase was collected, filtered through celite, washed

with brine, dried over MgSO_4 and concentrated. The residue was dissolved in DMSO and purified using preparative HPLC to give 895 mg (56%) of the title compound.

^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ ppm 9.18 (s, 1 H) 8.97 (s, 2 H) 8.74 (d, 1 H) 8.71 (d, 1 H) 7.89 (t, 1 H) 7.71 - 7.75 (m, 1 H) 7.62 - 7.65 (m, 1 H) 7.47 (t, 1 H) 7.22 (s, 2 H) 7.04 (br. s., 2 H) 3.58 (s, 3 H) 2.13 (s, 6 H); MS (ES) m/z 423 $[\text{M}+1]^+$.

Example 2


5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine



Chiral separation of 5-(4-methoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine into its isomers was performed on a Chiralpak IA column (50*300 mm) using 15% EtOH+0.1%DEA / 85% *n*-heptane as mobile phase with a flowrate of 120mL/min.

Isomer 1, E1: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ ppm 9.18 (s, 1 H) 8.97 (s, 2 H) 8.72 - 8.76 (m, 1 H) 8.69 - 8.72 (m, 1 H) 7.89 (t, 1 H) 7.71 - 7.75 (m, 1 H) 7.61 - 7.65 (m, 1 H) 7.45 - 7.50 (m, 1 H) 7.22 (s, 2 H) 7.04 (br. s., 2 H) 3.58 (s, 3 H) 2.13 (s, 6 H); MS (ES) m/z 423 $[\text{M}+1]^+$.


Isomer 2, E2: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 9.18 (s, 1 H) 8.98 (s, 2 H) 8.73 - 8.77 (m, 1 H) 8.70 - 8.73 (m, 1 H) 7.88 (t, 1 H) 7.70 - 7.75 (m, 1 H) 7.61 - 7.66 (m, 1 H) 7.45 - 7.50 (m, 1 H) 7.22 (s, 2 H) 7.07 (br. s, 2 H) 3.57 (s, 3 H) 2.13 (s, 6 H); MS (ES) m/z 423 $[\text{M}+1]^+$.

Example 3**5-(3-Chloro-4-methoxy-5-methylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**

5 The title compound was synthesized as described for Example 1 in 58% yield starting from 5-(3-bromophenyl)-5-(3-chloro-4-methoxy-5-methylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine (0.33g, 0.74mmol) and pyrimidin-5-ylboronic acid (138mg, 1.12mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.18 (s, 1 H) 8.99 (s, 2 H) 8.76 - 8.79 (m, 1 H) 8.73 - 8.76 (m, 1 H) 7.87 (t, 1 H) 7.69 - 7.74 (m, 1 H) 7.63 - 7.68 (m, 1 H) 7.46 - 7.52 (m, 2 H) 7.41 - 7.45 (m, 1 H) 7.18 (br. s., 2 H) 3.68 (s, 3 H) 2.20 (s, 3 H); MS (ES) *m/z* 443 [M+1]⁺.

10

Example 4**5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrazin-2-yl)phenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**

15 5-(3-Bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine (0.54g, 1.28 mmol), 2-(tributylstannyl)pyrazine (0.442 mL, 1.40 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.147 g, 0.13 mmol) were dissolved in DMF (5 mL) and heated for 60 min to 180 °C in a microwave oven. Water was added and the mixture was extracted with DCM (3x). The organic phases were pooled, dried over MgSO₄ and concentrated. Chromatography on silica using 0 - 4.5% MeOH (containing approx. 3.5 N NH₃) in DCM as eluent and final purification using preparative HPLC gave 97 mg (18%) of the title compound.


20

^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ ppm 9.11 - 9.16 (m, 1 H) 8.74 - 8.77 (m, 1 H) 8.69 - 8.73 (m, 2 H) 8.58 - 8.62 (m, 1 H) 8.37 (s, 1 H) 7.94 - 7.99 (m, 1 H) 7.72 - 7.78 (m, 1 H) 7.46 (t, 1 H) 7.20 (s, 2 H) 7.06 (br. s., 2 H) 3.58 (s, 3 H) 2.14 (s, 6 H); MS (ES) m/z 423 $[\text{M}+1]^+$.

5

Example 5

5-(3-Cyclopropyl-4-methoxyphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine




10 Pyrimidin-5-ylboronic acid (93 mg, 0.75 mmol), 5-(3-chlorophenyl)-5-(3-cyclopropyl-4-methoxyphenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine (245mg, 0.63 mmol), tricyclohexyl phosphine (52.7 mg, 0.19 mmol), tris(dibenzylideneacetone)dipalladium(0) (43.0 mg, 0.05 mmol) and potassium orthophosphate (226 mg, 1.07 mmol) were dissolved in DME (4.5 mL) and water (0.5 mL) and the mixture was heated for 3 h to 120 °C using a microwave
15 reactor. EtOAc, water and brine were added to the mixture. The organic phase was collected, filtered through celite, washed with brine, dried over MgSO_4 and concentrated. The residue was purified using preparative HPLC to give 110 mg (40%) of the title compound.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 9.19 (s, 1 H) 8.96 (s, 2 H) 8.70 - 8.75 (m, 2 H) 7.84
20 (t, 1 H) 7.62 - 7.69 (m, 2 H) 7.46 (t, 1 H) 7.35 - 7.40 (m, 1 H) 7.06 - 7.12 (m, 3 H) 6.85 (d, 1 H) 3.75 (s, 3 H) 1.96 - 2.04 (m, 1 H) 0.81 - 0.88 (m, 2 H) 0.39 - 0.45 (m, 2 H); MS (ES) m/z 435 $[\text{M}+1]^+$.

Example 6

25 **5-(2-Cyclopropylpyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine**




The title compound was synthesized as described for Example 1 in 53% yield starting from pyrimidin-5-ylboronic acid (38.9 mg, 0.31 mmol) and 5-(3-bromophenyl)-5-(2-cyclopropylpyridin-4-yl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine (85mg, 0.21 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.19 (s, 1 H) 9.00 (s, 2 H) 8.75 - 8.79 (m, 2 H) 8.26 - 8.30 (m, 1 H) 7.93 (t, 1 H) 7.72 - 7.77 (m, 1 H) 7.66 - 7.70 (m, 1 H) 7.50 (t, 1 H) 7.45 - 7.48 (m, 1 H) 7.29 - 7.32 (m, 1 H) 7.24 (br. s., 2 H) 1.98 - 2.06 (m, 1 H) 0.82 - 0.89 (m, 4 H); MS (ES) *m/z* 406 [M+1]⁺.


Example 7

5-(2-(Benzyloxy)pyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine




The title compound was synthesized as described for Example 1 in 39% yield starting from pyrimidin-5-ylboronic acid (61.0 mg, 0.49 mmol) and 5-(2-(benzyloxy)pyridin-4-yl)-5-(3-bromophenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine (155mg, 0.33 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.19 (s, 1 H) 8.99 (s, 2 H) 8.75 - 8.78 (m, 2 H) 8.06 - 8.09 (m, 1 H) 7.93 (t, 1 H) 7.73 - 7.77 (m, 1 H) 7.66 - 7.70 (m, 1 H) 7.50 (t, 1 H) 7.38 - 7.42 (m, 2 H) 7.28 - 7.37 (m, 3 H) 7.24 (br. s., 2 H) 7.17 - 7.20 (m, 1 H) 6.96 - 6.99 (m, 1 H) 5.28 (s, 2 H); MS (ES) *m/z* 472 [M+1]⁺.

Example 8**(R)- and (S)-5-(3-Fluoro-4-methoxy-5-methylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**


5 The title compound was synthesized as described for Example 1 in 47% yield starting from pyrimidin-5-ylboronic acid (69.7 mg, 0.56 mmol) and 5-(3-bromophenyl)-5-(3-fluoro-4-methoxy-5-methylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine (185 mg, 0.43 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.18 (s, 1 H) 8.99 (s, 2 H) 8.71 - 8.79 (m, 2 H) 7.88 (t, 1 H) 7.69 - 7.74 (m, 1 H) 7.64 - 7.68 (m, 1 H) 7.48 (t, 1 H) 7.21 - 7.27 (m, 2 H) 7.16 (br.
10 s., 2 H) 3.75 (d, 3 H) 2.16 (s, 3 H); MS (ES) *m/z* 427 [M+1]⁺.

Example 9**5-(4-Ethoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**


15 The title compound was synthesized as described for Example 1 in 72% yield starting from pyrimidin-5-ylboronic acid (55.2 mg, 0.45 mmol) and 5-(3-bromophenyl)-5-(4-ethoxy-3,5-dimethylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine (130mg, 0.30 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.19 (s, 1 H) 8.98 (s, 2 H) 8.74 - 8.76 (m, 1 H) 8.70
20 - 8.73 (m, 1 H) 7.90 (t, 1 H) 7.72 - 7.76 (m, 1 H) 7.62 - 7.67 (m, 1 H) 7.48 (t, 1 H) 7.22 (s, 2 H) 7.07 (s, 2 H) 3.72 (q, 2 H) 2.13 (s, 6 H) 1.29 (t, 3 H); MS (ES) *m/z* 437 [M+1]⁺.

Example 10**5-(4-Cyclopropoxy-3-fluoro-5-methylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine**

5 The title compound was synthesized as described for Example 1 in 34% yield starting from pyrimidin-5-ylboronic acid (28.7 mg, 0.23 mmol) and 5-(3-bromophenyl)-5-(4-cyclopropoxy-3-fluoro-5-methylphenyl)-5H-pyrrolo[3,4-*b*]pyrazin-7-amine (70mg, 0.15 mmol).

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 9.18 (s, 1 H) 8.99 (s, 2 H) 8.77 (d, 1 H) 8.74 (d, 1 H) 7.89 (t, 1 H) 7.71 - 7.76 (m, 1 H) 7.63 - 7.68 (m, 1 H) 7.49 (t, 1 H) 7.23 - 7.28 (m, 2 H) 7.13 (br. s., 2 H) 4.02 - 4.08 (m, 1 H) 2.11 (s, 3 H) 0.65 - 0.70 (m, 2 H) 0.50 - 0.56 (m, 2 H); MS (ES) *m/z* 453 [M+1]⁺.

Example 11**7-(3-Cyclopropyl-4-methoxy-5-methyl-phenyl)-7-(3-pyrimidin-5-yl-phenyl)-7H-pyrrolo[3,4-*b*]pyrazin-5-ylamine**


K₃PO₄ (57 mg, 0.26 mmol) and pyrimidine-5-boronic acid (112 mg, 0.89 mmol) were added to a degassed solution of 7-(3-Chloro-phenyl)-7-(3-cyclopropyl-4-methoxy-5-methyl-phenyl)-7H-pyrrolo[3,4-*b*]pyrazin-5-ylamine (75 mg, 0.18 mmol) in DME (14 mL), followed by 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (18 mg, 0.04 mmol) and Pd₂dba₃ (17 mg, 0.02 mmol). The reaction mixture was heated in a microwave reactor at 120 °C for 1 hour. Water (30 mL) was added and the mixture was extracted with EtOAc (3 x 30 mL). The combined extracts were dried over MgSO₄, filtered and

concentrated *in vacuo*. The residue was purified by preparative TLC using 5% MeOH (2M NH₃) in DCM to afford the title compound (41 mg, 51%).

¹H NMR (400 MHz, CDCl₃) δ ppm 9.18 (s, 1 H), 8.89 (s, 2 H), 8.66 (d, 1 H), 8.57 (d, 1 H), 7.80 (s, 1 H), 7.69 (m, 1 H), 7.41 - 7.48 (m, 2 H), 7.16 - 7.20 (m, 1 H), 6.89 (d, 1 H), 3.76 (s, 3 H), 2.23 (s, 3 H), 2.13 (m, 1 H), 0.87 - 0.94 (m, 2 H), 0.58 (m, 2 H); MS (ES) *m/z* 449 [M+1]⁺.

Example 12

5-(3-(5-Chloropyridin-3-yl)phenyl)-5-(2-cyclopropylpyridin-4-yl)-5H-pyrrolo[3,4-b]pyrazin-7-amine




The title compound was synthesized as described for Example 1 in 38% yield starting from 5-chloropyridin-3-ylboronic acid (49.4 mg, 0.31 mmol) and 5-(3-bromophenyl)-5-(2-cyclopropylpyridin-4-yl)-5H-pyrrolo[3,4-b]pyrazin-7-amine (85mg, 0.21 mmol).

¹H NMR (400 MHz, DMSO-*d*₆) ppm 8.77 - 8.79 (m, 1 H) 8.75 - 8.77 (m, 1 H) 8.71 (d, 1 H) 8.63 (d, 1 H) 8.27 - 8.30 (m, 1 H) 8.10 (t, 1 H) 7.92 (t, 1 H) 7.72 - 7.76 (m, 1 H) 7.62 - 7.67 (m, 1 H) 7.43 - 7.51 (m, 2 H) 7.27 - 7.30 (m, 1 H) 7.24 (br. s., 2 H) 1.98 - 2.05 (m, 1 H) 0.82 - 0.89 (m, 4 H); MS (ES) *m/z* 439 [M+1]⁺.

Example 13

(S)-5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrazin-2-yl)phenyl)-5H-pyrrolo[3,4-b]pyrazin-7-amine




(R)-5-(3-bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5H-pyrrolo[3,4-b]pyrazin-7-amine (0.67 g, 1.58 mmol), tetrakis(triphenylphosphine)palladium(0) (0.183 g, 0.16 mmol) and 2-(tributylstannyl)pyrazine (0.643 g, 1.74 mmol) were dissolved in DMF (4.5 mL) and heated to 120 °C with MW for 30 min. The mixture was partitioned between ACN and n-heptane. ACN was evaporated and the residue was placed on a silica column eluting with MeOH(containing 7N NH₃) from 0-2.5% in DCM to give 236mg (35% yield) of the title compound with 99.5% enantiomeric purity (Chiral HPLC analysis; 20% EtOH+DEA 80% CO₂ on Chiralpak AD-H 4.6*250 mm 5µm at 3mL/min using 5-(4-methoxy-3,5-dimethylphenyl)-5-(3(pyrazin-2-yl)phenyl)-5H-pyrrolo[3,4-b]pyrazin-7-amine as reference).

¹H NMR (500 MHz, DMSO-*d*₆) ppm 9.13 (d, 1 H) 8.75 (d, 1 H) 8.69 - 8.73 (m, 2 H) 8.60 (d, 1 H) 8.36 (t, 1 H) 7.94 - 7.98 (m, 1 H) 7.72 - 7.76 (m, 1 H) 7.45 (t, 1 H) 7.19 (s, 2 H) 7.08 (br. s., 2 H) 3.58 (s, 3 H) 2.13 (s, 6 H); MS (ES) *m/z* 423 [M+1]⁺.

Example 14

(R)- and (S)-5-(2-Cyclopropylpyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5H-pyrrolo[3,4-b]pyrazin-7-amine




preparative HPLC system (Chiralpak AD-H column, 21.2*250 mm, using 25% IPA+DEA / 75% CO₂ as mobile phase at a flow rate of 50 mL/min at 35 °C).

Isomer 1 with unknown absolute configuration, the first enantiomer to elute was collected (14 mg, 33% yield): ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 0.77 - 0.93 (m, 4 H), 1.98 - 2.06 (m, 1 H), 7.23 (br. s., 2 H), 7.31 (dd, 1 H), 7.47 (d, 1 H), 7.50 (t, 1 H), 7.65 - 7.72 (m, 1 H), 7.72 - 7.78 (m, 1 H), 7.93 (t, 1 H), 8.28 (d, 1 H), 8.74 - 8.82 (m, 2 H), 9.00 (s, 2 H), 9.19 (s, 1 H); MS (ES+) *m/z* 406 [M+H]⁺.

Isomer 2 with unknown absolute configuration, the second enantiomer to elute was collected (13 mg, 31% yield): ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 0.80 - 0.90 (m, 4 H), 1.98 - 2.05 (m, 1 H), 7.23 (br. s., 2 H), 7.31 (dd, 1 H), 7.47 (d, 1 H), 7.50 (t, 1 H), 7.66 - 7.70 (m, 1 H), 7.75 (dt, 1 H), 7.93 (t, 1 H), 8.28 (d, 1 H), 8.75 - 8.80 (m, 2 H), 9.00 (s, 2 H), 9.19 (s, 1 H); MS (ES+) *m/z* 406 [M+H]⁺.

Example 15

(S)-5-(4-methoxy-3,5-dimethylphenyl)-5-(3-(5-(prop-1-ynyl)pyridin-3-yl)phenyl)-5H-pyrrolo[3,4-b]pyrazin-7-amine



(R)-5-(3-bromophenyl)-5-(4-methoxy-3,5-dimethylphenyl)-5H-pyrrolo[3,4-b]pyrazin-7-amine (66 mg, 0.16 mmol), 5-(prop-1-ynyl)pyridin-3-yl boronic acid (37.6 mg, 0.23 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride (6.41 mg, 7.80 μmol), 2M aqueous Potassium carbonate (0.195 mL, 0.39 mmol) and 1,4-dioxane (2 mL) were mixed and stirred under a nitrogen atmosphere at 90 °C for 2 h. More 5-(prop-1-ynyl)pyridin-3-ylboronic acid (37.6 mg, 0.23 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride (6.41 mg, 7.80 μmol) and potassium carbonate (0.195 mL, 0.39 mmol) were added and stirring continued at 90 °C for 2 h. When cooled to rt, the mixture was diluted with MeOH, filtered and purified by

preparative HPLC. The fractions containing the title compound were pooled, the MeOH removed *in vacuo* and the resulting aqueous residue was diluted with saturated aqueous NaHCO₃ and extracted with DCM. The combined organics were passed through a phase separator, and the organic phase was collected and concentrated. The crude product was further purified on a silica gel column eluted with 0-10% (0.1M NH₃ in MeOH) in DCM to give 24 mg (34% yield) of the title compound.

¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 8.73 (d, 2 H) 8.67 (s, 1 H) 8.57 (s, 1 H) 7.91 (s, 1 H) 7.85 (s, 1 H) 7.70 (d, 1 H) 7.58 (d, 1 H) 7.39 - 7.47 (m, 1 H) 7.20 (s, 2 H) 7.07 (br. s., 2 H) 3.57 (s, 3 H) 2.13 (s, 6 H) 2.11 (s, 3 H); MS (ES) *m/z* 460 [M+1]⁺.

Assays

The level of activity of the compounds was tested using the following methods:

β-Secretase Enzyme

The enzyme used in the TR-FRET- and the BiaCore-assays is described as follows:

The cDNA for the soluble part of the human β-Secretase (AA 1 – AA 460) was cloned using the ASP2-Fc10-1-IRES-GFP-neoK mammalian expression vector. The gene was fused to the Fc domain of IgG1 (affinity tag) and stably cloned into HEK 293 cells. Purified sBACE-Fc is stored in -80°C in Tris buffer, pH 9.2 and has a purity of 95%.

TR-FRET Assay

The β-Secretase enzyme used in the TR-FRET assay is described as follows:

The cDNA for the soluble part of the human β-Secretase (AA 1 – AA 460) is expressed with a C-terminal Fc-fusion tag in HEK-293 cells. sBACE-Fc is purified using expanded bed adsorption over rPoteinA. The culture broth is not adjusted to pH. The resin is washed with PBS pH 7.4 and elution of BACE-Fc is performed with 50 mM glycine pH 2.5. The pH is immediately adjusted to pH 7.4 with 1M Tris-base. No protease inhibitors are added. Purified sBACE-Fc is stored in -80 °C, and has a purity of 40%.

The enzyme (truncated form) is diluted to 6 µg/mL (stock 1.3 mg/mL) and the substrate (Europium)CEVNLDAEFK(Qsy7) to 200 nM (stock 120 µM) in reaction buffer (NaAcetate, chaps, triton x-100, EDTA pH4.5). The robotic systems Biomek FX and Velocity 11 are used for all liquid handling and the enzyme and substrate solutions are kept

on ice until they are placed in the robotic system. Enzyme (9 μ L) is added to the plate then 1 μ L of compound in dimethylsulphoxide is added, mixed and pre-incubated for 10 minutes. Substrate (10 μ L) is then added, mixed and the reaction proceeds for 15 minutes at room temperature. The reaction is stopped with the addition of Stop solution (7 μ L, NaAcetate, pH ~9). The fluorescence of the product is measured on a Victor II plate reader with an excitation wavelength of 340nm and an emission wavelength of 615nm. The assay is performed in a Costar 384 well round bottom, low volume, non-binding surface plate (Corning #3676). The final concentration of the enzyme is 2.7 μ g/mL; the final concentration of substrate is 100 nM (K_m of ~250 nM). The dimethylsulphoxide control, instead of test compound, defines the 100% activity level and 0% activity is defined by wells lacking enzyme (replaced with reaction buffer). A control inhibitor is also used in dose response assays and has an IC_{50} of ~575 nM.

sAPP β release assay

SH-SY5Y cells are cultured in DMEM /F-12 with Glutamax, 10% FCS and 1% non-essential aminoacids and cryopreserved and stored at -140°C at a concentration of 7.5×10^6 cells per vial. Thaw cells and seed at a concentration of 2×10^5 /mL in DMEM /F-12 with Glutamax, 10% FCS and 1% non-essential aminoacids to a 384-well tissue culture treated plate, 30 μ L cell suspension/well. Alternatively, use a 96-well tissue culture treated plate, and seed the cells at a concentration of 1.5×10^5 /mL in DMEM /F-12 with Glutamax, 10% FCS and 1% non-essential aminoacids, 100 μ L cell suspension/well. The cell plates are then incubated for 7 hours at 37°C , 5% CO_2 and the cell medium is then removed. In 384 well mode this is followed by the addition to each well of 30 μ L compound diluted in DMEM /F-12 with Glutamax, 10% FCS, 1% non-essential aminoacids and 1% PeSt to a final conc of 1% DMSO. In 96 well mode the removal of cell medium is followed by the addition to each well of 90 μ L compound diluted in DMEM /F-12 with Glutamax, 10% FCS, 1% non-essential aminoacids and 1% PeSt to a final conc of 1% DMSO. The compounds are incubated with the cells for 16h (over night) at 37°C , 5% CO_2 .

Meso Scale Discovery (MSD) plates are used for the detection of sAPP β release.

MSD sAPP β plates are blocked in 3% BSA in Tris wash buffer (40 μ L/well in 384-format or 150 μ L/well in 96-format) for 1 hour in RT and washed 4 times in Tris wash buffer (40 μ L/well in 384-format or 150 μ L/well in 96-format). 20 μ L (384-format) or 50 μ L (96-

format) of medium is transferred to the pre-blocked and washed 384 well or 96 well MSD sAPP β microplates, and the cell plates are further used in an ATP assay to measure cytotoxicity. The MSD plates are incubated with shaking in RT for 2 hours (384-format) or 1 hour (96-format) followed by washing 4 times. 10 μ L (384-format) or 25 μ L (96-format) detection antibody is added (1nM) per well followed by incubation with shaking in RT for 2 hours (384-format) or 1 hour (96-format) followed by washing 4 times. 40 μ L (384-format) or 150 μ L (96-format) Read Buffer is added per well and the plates are read in a SECTOR Imager.

ATP assay

As indicated in the sAPP β release assay, after transferring 20 μ L (384-format) or 50 μ L (96-format) medium from the cell plates for sAPP β detection, the plates are used to analyse cytotoxicity using the ViaLightTM Plus cell proliferation/cytotoxicity kit from Cambrex BioScience that measures total cellular ATP.

The assay is performed according to the manufacture's protocol. Briefly, 10 μ L (384-format) or 25 μ L (96-format) cell lysis reagent is added per well. The plates are incubated at room temperature for 10 min.

Two min after addition of 25 μ L (384-format) or 50 μ L (96-format) reconstituted ViaLightTM Plus ATP reagent, the luminescence is measured in a Wallac Victor2 1420 multilabel counter.

Results


Typical IC₅₀ values for the compounds of the present invention are in the range of about 0.1 to about 30,000 nM. Biological data on exemplified final compounds is given below in Table I.

Table I.

Example No.	IC50 in TR-FRET assay
Example 1	30
Example 2 Isomer 1	13000
Example 2 Isomer 2	20
Example 3	34
Example 4	50
Example 5	200
Example 6	130
Example 7	79
Example 8	89
Example 9	140
Example 10	190
Example 11	110
Example 12	74
Example 13	27
Example 14 Isomer 1	105
Example 14 Isomer 2	4110
Example 15	10

CLAIMS

1. A compound according to formula (I)



(I)

5 wherein

A is aryl or heteroaryl, wherein said aryl or heteroaryl is optionally substituted with one to three R^1 ;

G is aryl or heteroaryl, wherein said aryl or heteroaryl is optionally substituted with one to three R^2 ;

10 R^1 is selected from halogen, C_{1-4} alkyl, OR^3 , C_{3-6} carbocyclyl, C_{1-4} haloalkyl, C_{1-4} alkylOH, and hydroxy;

R^2 is selected from halogen, C_{1-3} alkoxy, C_{2-6} alkenyl, C_{1-3} alkyl, and C_{2-6} alkynyl;

R^3 is selected from C_{1-4} alkyl, C_{1-4} alkylaryl, C_{3-6} carbocyclyl, C_{1-4} alkylheteroaryl and C_{1-4} alkylOC $_{1-4}$ alkyl;

15 R^5 is selected from fluoro and hydroxy;

m is 0, 1 or 2;

as a free base or a pharmaceutically acceptable salt thereof.

20 2. A compound according to claim 1, wherein A is phenyl or pyridine, substituted with one to three R^1 .

3. A compound according to claim 1 or claim 2, wherein G is pyridine, pyrimidine or pyrazine, optionally substituted with one R^2 .

25 4. A compound according to any one of claims 1 to 3, wherein R^1 is halogen, C_{1-4} alkyl, C_{3-6} carbocyclyl, or OR^3 .

5. A compound according to claim 4, wherein R¹ is halogen, methyl, cyclopropyl or methoxy.
6. A compound according to any one of claims 1 to 5, wherein R² is halogen, or C₂₋₆alkynyl.
7. A compound according to any one of claims 1 to 6, wherein R³ is methyl, ethyl, cyclopropyl or benzyl.
8. A compound according to any one of claims 1-7, wherein m is 0.
9. A compound according to claim 1, wherein
A is phenyl or pyridine;
G is pyrimidine, pyridine or pyrazine;
R¹ is halogen, methyl, cyclopropyl, or OR³;
R² is halogen, or C₂₋₆alkynyl;
R³ is methyl, ethyl, cyclopropyl, or CH₂Ph; and
m is zero.
10. A compound according to claim 1 selected from
5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;
(*R*)- and (*S*)-5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;
5-(3-Chloro-4-methoxy-5-methylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;
5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrazin-2-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;
5-(3-Cyclopropyl-4-methoxyphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5-(2-Cyclopropylpyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5-(2-(Benzyloxy)pyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5 5-(3-Fluoro-4-methoxy-5-methylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

5-(4-Ethoxy-3,5-dimethylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

10 5-(4-Cyclopropoxy-3-fluoro-5-methylphenyl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

7-(3-Cyclopropyl-4-methoxy-5-methyl-phenyl)-7-(3-pyrimidin-5-yl-phenyl)-7*H*-pyrrolo[3,4-*b*]pyrazin-5-ylamine;

5-(3-(5-Chloropyridin-3-yl)phenyl)-5-(2-cyclopropylpyridin-4-yl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

15 (S)-5-(4-Methoxy-3,5-dimethylphenyl)-5-(3-(pyrazin-2-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

(R)-5-(2-Cyclopropylpyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

20 (S)-5-(2-Cyclopropylpyridin-4-yl)-5-(3-(pyrimidin-5-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

(S)-5-(4-methoxy-3,5-dimethylphenyl)-5-(3-(5-(prop-1-ynyl)pyridin-3-yl)phenyl)-5*H*-pyrrolo[3,4-*b*]pyrazin-7-amine;

as a free base or a pharmaceutically acceptable salt thereof.

25 11. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 1 to 10 in association with pharmaceutically acceptable excipients, carriers or diluents.

12. A compound according to any one of claims 1 to 10, or a pharmaceutically
30 acceptable salt thereof, for use as a medicament.

13. A compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, as a medicament for treating or preventing an A β -related pathology.

14. A compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, as a medicament for treating or preventing an A β -related pathology, wherein said A β -related pathology is Down's syndrome, a β -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

15. A compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, as a medicament for treating or preventing Alzheimer Disease.

16. A compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing an A β -related pathology.

17. Use of a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing an A β -related pathology, wherein said A β -related pathology is Down's syndrome, a β -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

18. Use of a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing Alzheimer's Disease.

5 19. A method of treating or preventing an A β -related pathology in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof.

10 20. The method of claim 19, wherein said A β -related pathology is Downs syndrome, a β -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia
15 associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

21. A method of treating or preventing an A β -related pathology in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a
20 compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2010/050761

A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC:A61K, A61P, C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, PAJ, WPI data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 20080287462 A1 (CHESSARI GIANNI ET AL), 20 November 2008 (2008-11-20); abstract; page 1, column 1, line 5 - page 1, column 1, line 19; claims 1, 40-52; examples 6-12, 16-17, 21-23	1-21
X	-- WO 2007149033 A1 (ASTRAZENECA AB ET AL), 27 December 2007 (2007-12-27); page 1, line 4 - page 1, line 13; claims 1, 12-13, 17-20; examples 15-18, 27-28, 30-33, 44-47, 59-60, 62-63, 66-69, 71-76, 100-101, 103-105, 111-115, 117, 121-122, 124-125, 130	1-21
P, X	-- WO 2010056194 A1 (ASTRAZENECA AB ET AL), 20 May 2010 (2010-05-20); page 1, line 3 - page 1, line 12; claims 1, 23, 26-31; examples 1-4, 10, 14, 19-21, 25, 37-38	1-21
A	-- WO 2009005471 A1 (ASTRAZENECA AB ET AL), 8 January 2009 (2009-01-08)	1-21
A	-- WO 2009005470 A1 (ASTRAZENECA AB ET AL), 8 January 2009 (2009-01-08)	1-21
	--	

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

08-10-2010

Date of mailing of the international search report

08-10-2010

Name and mailing address of the ISA/SE

Patent- och registreringsverket

Box 5055

S-102 42 STOCKHOLM

Facsimile No. + 46 8 666 02 85

Authorized officer

Anna Ax

Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE2010/050761

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 19-21
because they relate to subject matter not required to be searched by this Authority, namely:

Claims 19-21 relate to a method for treatment of the human or animal body by therapy, see PCT rule 39.1(iv). Nevertheless, a search has been made for these claims. The search has been directed to the technical content of the claims.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of: second sheet

International Patent Classification (IPC)

C07D 487/04 (2006.01)

A61K 31/4985 (2006.01)

A61P 25/28 (2006.01)

Download your patent documents at www.prv.se

The cited patent documents can be downloaded:

- From "Cited documents" found under our online services at www.prv.se
(English version)
- From "Anförda dokument" found under "e-tjänster" at www.prv.se
(Swedish version)

Use the application number as username. The password is **JLEQPAMDWK**.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85).

Cited literature, if any, will be enclosed in paper form.

International application No.
PCT/SE2010/050761

Form PCT/ISA/210 (patent family annex) (July 2009)